

Haematologica

Journal of Hematology

founded in 1920 by Adolfo Ferrata

*Official Organ of
the Italian Society of Hematology,
the Italian Society of Experimental Hematology and
the Spanish Association of Hematology and Hemotherapy*

Publication Policy Committee

Edoardo Storti (Chair, Pavia), Fausto Grignani (Perugia), Lucio Luzzatto (New York), Franco Mandelli (Roma), Massimo F. Martelli (Perugia), Emilio Montserrat (Barcelona), Alessandro Pileri (Torino), Vittorio Rizzoli (Parma), Eduardo Rocha (Pamplona), Pierluigi Rossi Ferrini (Firenze), Sante Tura (Bologna), Soledad Woessner (Barcelona)

Editor-in-Chief

Edoardo Ascari (Pavia)

Co-Editors

Carlo Bernasconi (President of the Italian Society of Hematology, Pavia), Ciril Rozman (Representative of the Spanish Association of Hematology and Hemotherapy, Barcelona), Giuseppe Saglio (President of the Italian Society of Experimental Hematology, Torino)

Executive Editor

Mario Cazzola (Pavia)

Editorial Board

Claudio Anasetti (Seattle)
Michele Baccharani (Udine)
Andrea Bacigalupo (Genova)
Carlo Balduini (Pavia)
Luz Barbolla (Madrid)
Tiziano Barbui (Bergamo)
Giovanni Barosi (Pavia)
Yves Beguin (Liège)
Niels Borregard (Copenhagen)
Gary Brittenham (Cleveland)
Carlo Brugnara (Boston)
Salut Brunet (Barcelona)
Federico Caligaris Cappio (Torino)
Dario Campana (Memphis)
Maria Domenica Cappellini (Milano)
Carmelo Carlo-Stella (Parma)
Nicole Casadevall (Garches)
Gianluigi Castoldi (Ferrara)
Marco Cattaneo (Milano)
Christine Chomienne (Paris)
Alan Cohen (Philadelphia)
Eulogio Conde (Santander)
Björn Dahlbäck (Malmö)

Armando D'Angelo (Milano)
Elisabetta Dejana (Milano)
Maria Consuelo del Cañizo (Salamanca)
José M. Fernandez Rañada (Madrid)
Jordi Fontcuberta (Barcelona)
Francesco Frassoni (Genova)
Frédéric Galacteros (Creteil)
Renzo Galanello (Cagliari)
Arnold Ganser (Hannover)
Paolo G. Gobbi (Pavia)
Alberto Grañena (Barcelona)
Eva Helström-Lindberg (Huddinge)
Rosangela Invernizzi (Pavia)
Achille Iolascon (Bari)
Sakari Knuutila (Helsinki)
Catherine Lacombe (Paris)
Roberto Lemoli (Bologna)
Alessandro Levis (Alessandria)
Franco Locatelli (Pavia)
Francesco Lo Coco (Roma)
Ignazio Majolino (Palermo)
Patrice Mannoni (Marseille)
Estella Matutes (London)
Roberto Mazzara (Barcelona)

Cristina Mecucci (Perugia)
Giampaolo Merlini (Pavia)
Alberto Orfao (Salamanca)
Rose Ann Padua (Paris)
Pier Paolo Pandolfi (New York)
Luigi Pegoraro (Torino)
Franco Piovella (Pavia)
Giovanni Pizzolo (Verona)
Alessandro Rambaldi (Bergamo)
Paolo Rebulla (Milano)
Yair Reisner (Rehovot)
Francesco Rodeghiero (Vicenza)
Bruno Rotoli (Napoli)
Jesús F. San Miguel (Salamanca)
Guillermo F. Sanz (Valencia)
Miguel A. Sanz (Valencia)
Jordi Sierra (Barcelona)
Pieter Sonneveld (Rotterdam)
Giuseppe Torelli (Modena)
Antonio Torres (Cordoba)
Vicente Vicente (Murcia)
Ana Villegas (Madrid)
Françoise Wendling (Paris)

Editorial Office – Michele Moscato, Lorella Ripari, Joseph Strohofer

Published on behalf of the Ferrata Storti Foundation by

IL PENSIERO SCIENTIFICO EDITORE, ROME

EDICIONES DOYMA, BARCELONA

Internet edition: www.medit.it/haematologica

Editorial policy, subscriptions and advertisements

Editorial Policy

Haematologica is owned by the Ferrata-Storti Foundation, a non-profit organization created through the efforts of the heirs of Professor Adolfo Ferrata and of Professor Edoardo Storti. The aim of the Ferrata-Storti Foundation is to stimulate and promote the study of and research on blood disorders and their treatment in several ways, in particular by supporting and expanding **Haematologica**. The journal is published on behalf of the Ferrata-Storti Foundation by Il Pensiero Scientifico Editore, Rome, Italy and Ediciones Doyma, Barcelona, Spain.

The content of **Haematologica** is protected by copyright. Papers are accepted for publication with the understanding that their contents, all or in part, have not been published elsewhere, except in abstract form or by express consent of the Editor-in-Chief or the Executive Editor. Further details on transfer of copyright and permission to reproduce parts of published papers are given in *Instructions to Authors*.

Editorial correspondence should be addressed to:

The Editorial Office, **Haematologica**, Strada Nuova 134, 27100 Pavia, Italy (Tel. international +39.382.531182. Fax. international +39.382.27721; e-mail: haema@telnetwork.it)

Haematologica accepts no responsibility for statements made by contributors or claims made by advertisers.

Subscription rate for Volume 82 (1997): 170,000 Lit. in Italy, 220,000 Italian Lit. abroad. Orders and inquires should be addressed to: Il Pensiero Scientifico Editore, via Bradano 3c, 00199 Rome, Italy (Tel. international +39.6.86207158; Fax international +39.6.86207160; e-mail pensiero@pensiero.it; website <http://www.pensiero.it>)

Communications concerning changes of address should be addressed to the Publisher. They should include both old and new addresses and should be accompanied by a mailing label from a recent issue.

Inquires about single or replacement copies of **Haematologica** should be addressed to the Publisher.

Advertisements

Inquires should be addressed to:

Il Pensiero Scientifico Editore, Servizi di Comunicazione Integrata, via Bradano 3c, 00199 Rome, Italy (Tel. international +39.6.86207165; Fax international +39.6.86207160; e-mail pensiero@pensiero.it)

Notizie amministrative 1997

Abbonamento annuo: 6 fascicoli bimestrali

Istituti, Enti e Biblioteche	Lit.	170.000
Privati:		
per l'Italia	Lit.	135.000
per l'estero	Lit.	220.000

Per i fascicoli arretrati sono validi i prezzi dell'anno corrente

Il prezzo dell'abbonamento può essere versato a mezzo assegno circolare su qualsiasi banca, o a mezzo vaglia postale, o rimessa sul c/c p. 902015, intestato a Il Pensiero Scientifico Editore, via Bradano 3c, 00199 Roma.

L'IVA è corrisposta dall'Editore (art. 74/C D.P.R. 633/72) e pertanto non si rilascia fattura.

Gli eventuali cambi di indirizzo debbono essere segnalati con preavviso di un mese dalla pubblicazione del numero per il quale il cambio viene richiesto.

In caso di disdetta dell'abbonamento è gradita una tempestiva comunicazione scritta.

Per i fascicoli eventualmente non ricevuti, l'abbonato potrà farne richiesta alla Casa Editrice entro l'anno della pubblicazione.

Le richieste per inserzioni pubblicitarie vanno indirizzate a:

Il Pensiero Scientifico Editore, Servizi di Comunicazione Integrata, via Bradano 3c, 00199 Roma, Italia (Tel. international +39.6.86207165; Fax international +39.6.86207160; e-mail pensiero@pensiero.it).



16 mm microfilm, 35 mm microfilm, 105 mm microfiche and article copies are available through University Microfilms International, 300 North Zeeb Road, Ann Arbor, Michigan 48106, USA



Associato all'USPI, Unione Stampa Periodica Italiana

Premiato per l'alto valore culturale dal Ministero dei Beni Culturali ed Ambientali

instructions to authors

Haematologica publishes bimonthly *Editorials*, *Original Papers*, *Case Reports*, *Reviews* and *Scientific Letters* on subjects regarding experimental, laboratory and clinical hematology. *Editorials* and *Reviews* are normally solicited by the Editor, but suitable papers of this type may be submitted for consideration. Appropriate papers are published under the headings *Decision Making and Problem Solving* and *The Irreplaceable Image*.

Review and Action. Submission of a paper implies that neither the article nor any essential part of it has been or will be published or submitted for publication elsewhere before appearing in **Haematologica**. All articles submitted for publication are reviewed by at least two different referees. After this peer examination, the final decision on a paper's acceptability for publication is made by the Editors, and this decision is transmitted to the authors along with copies of the reviewers' detailed comments.

Conflict of Interest Policies. Authors. Before final acceptance, authors of research papers or reviews will be asked to sign the following conflict of interest statement: *Please provide any pertinent information about the authors' personal or professional situation that might affect or appear to affect your views on the subject. In particular, disclose any financial support by companies interested in products or processes involved in the work described.* A footnote in the printed paper will indicate that the authors have disclosed a potential conflict of interest.

Reviewers. Reviewers are regularly asked to sign the following conflict of interest statement: Please indicate whether you have any relationship (personal or professional situation, in particular any financial interest) that might affect or appear to affect your judgment.

Articles written by Editorial Board Members. Research articles or reviews written by these members are regularly processed by the Editor-in-Chief and/or the Executive Editor.

Time to publication. **Haematologica** strives to be a forum for rapid exchange of new observations and ideas in hematology. As such, our objective is to review a paper in 3-4 weeks and communicate the editorial decision by fax within one month of submission.

Submit papers to:

the Editorial Office, *Haematologica*, Strada Nuova 134, 27100 Pavia, Italy.

Manuscripts must be written in English. Manuscripts with inconsistent spelling will be unified by the English Editor.

Manuscripts should be prepared according to the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals, N Engl J Med 1997; 336:309-15*. Manuscripts, including tables and figures, should be sent in triplicate to facilitate rapid reference. In order to accelerate processing, author(s) should also enclose a 3.5" diskette (MS-DOS or Macintosh) containing the manuscript text; if the paper includes computerized graphs, the diskette should contain these documents as well. Computer programs employed to prepare the above documents should be listed.

Title Page. The first page of the manuscript must contain: (a) title, name and surname of the authors; (b) names of the institution(s) where the research was carried out; (c) a running title of no more than 50 letters; (d) acknowledgements; (e) the name and full postal

address of the author to whom correspondence regarding the manuscript as well as requests for abstracts should be sent; (f) three to five key words. To accelerate communication, phone, fax number and e-mail address of the corresponding author should also be included.

Abstract. The second page should carry an informative abstract of no more than 250 words for structured abstracts or 150 words for unstructured abstracts; the unstructured abstracts should be intelligible without reference to the text. Original paper abstracts must be structured as follows: background and objective, methods, results, interpretation and conclusions.

Editorials should be concise. No particular format is required for these articles, which must not include any summary.

Original papers should normally be divided into abstract, introduction, materials and methods, results, discussion and references.

Case Reports should be no longer than 800 words, can include one or two figures and/or tables, and should not contain more than ten strictly relevant references. After a brief abstract, the text should include an introductory paragraph, a description of the case, and a comment. These manuscripts should be signed by no more than six authors.

The section *Decision Making and Problem Solving* presents papers on health decision science specifically regarding hematological problems. Suitable papers will include those dealing with public health, computer science and cognitive science. This section may also include guidelines for diagnosis and treatment of hematological disorders and position papers by scientific societies.

Reviews provide a comprehensive overview of issues of current interest. No particular format is required but the text should be preceded by an abstract which should be structured as follows: background and objective, evidence and information sources, state of art, perspectives. Within review articles, **Haematologica** gives top priority to: a) papers on molecular hematology to be published in the section *Molecular basis of disease*; b) papers on clinical problems analyzed according to the methodology typical of *Evidence-Based Medicine*.

The section *The Irreplaceable Image* deals with short papers containing pictures of particular interest: bone marrow or peripheral blood smears, biopsies, physical and radiographic findings, etc. No more than three authors should sign these papers.

Scientific letters should be no longer than 500 words (a word count should be included by the Authors), can include one or two figure or table, and should not contain more than ten strictly relevant references. Letters should be signed by no more than six authors. Correspondence, i.e. comments on articles published in the Journal will only appear in our Internet edition.

Tables and Illustrations. Tables and illustrations must be constructed in consideration of the size of the Journal and without repetitions. They should be sent in triplicate with each table typed on a separate page, progressively numbered with Arabic numerals and accompanied by a caption in English. All illustrations (graphs, drawings, schemes and photographs) must be progressively numbered with Arabic numerals. In place of original drawings, roentgenograms, or other materials, send sharp glossy black-and-white photographic prints, usually 13 by 18 cm but no larger than 20 by 25 cm. In preparing illustrations, the final base should be considered the width of a single column, i.e. 8 cm (larger illustrations will be accepted only in special cases). Letters and numbers should be large enough to remain legible (> 1 mm) after the fig-

ure has been reduced to fit the width of a single column. In preparing composite illustrations, each section should be marked with a small letter in the bottom left corner. Legends for illustrations should be typewritten on a separate page. Authors are also encouraged to submit illustrations as electronic files together with the manuscript text (please, provide what kind of computer and software employed).

Units of measurement. All hematologic and clinical chemistry measurements should be reported in the metric system according to the *International System of Units (SI)* (*Ann Intern Med* 1987; 106:114-29). Alternative non-SI units may be given in addition. Authors are required to use the standardized format for abbreviations and units of the *International Committee for Standardization in Hematology* when expressing blood count results (*Haematologica* 1991; 76:166).

References should be prepared according to the Vancouver style (for details see: *N Engl J Med* 1997; 336:309-15). References must be numbered consecutively in the order in which they are first cited in the text, and they must be identified in the text by arabic numerals (in parentheses). Journal abbreviations are those of the *List of the Journals Indexed*, printed annually in the January issue of *Index Medicus* [this list (about 1.3 Mb) can also be obtained on Internet through the US National Library of Medicine website, at the following address: <http://www.nlm.nih.gov/tsd/serials/lji.html>].

List all authors when six or fewer; when seven or more, list only the first three and add et al. Examples of correct forms of references follow (please note that the last page must be indicated with the minimum number of digits):

Journals (standard journal article,^{1,2} corporate author,³ no author given,⁴ journal supplement):

1. Najfeld V, Zucker-Franklin D, Adamson J, Singer J, Troy K, Fialkow PJ. Evidence for clonal development and stem cell origin of M7 megakaryocytic leukemia. *Leukemia* 1988; 2:351-7.
2. Burgess AW, Begley CG, Johnson GR, et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. *Blood* 1987; 69:43-51.
3. The Royal Marsden Hospital Bone-Marrow Transplantation Team. Failure of syngeneic bone-marrow graft without preconditioning in post-hepatitis marrow aplasia. *Lancet* 1977; 2:242-4.
4. Anonymous. Red cell aplasia [editorial]. *Lancet* 1982; 1:546-7.
5. Karlsson S, Humphries RK, Gluzman Y, Nienhuis AW. Transfer of genes into hemopoietic cells using recombinant DNA viruses [abstract]. *Blood* 1984; 64(Suppl 1):58a.

Books and other monographs (personal authors,^{6,7} chapter in a book,⁸ published proceeding paper,⁹ abstract book,¹⁰ monograph in a series,¹¹ agency publication¹²):

6. Ferrata A, Storti E. *Le malattie del sangue*. 2nd ed. Milano:

Vallardi; 1958.

7. Hillman RS, Finch CA. *Red cell manual*. 5th ed. Philadelphia: FA Davis; 1985.
8. Bottomley SS. Sideroblastic anaemia. In: Jacobs A, Worwood M, eds. *Iron in biochemistry and medicine, II*. London: Academic Press; 1980. p. 363-92.
9. DuPont B. Bone marrow transplantation in severe combined immunodeficiency with an unrelated MLC compatible donor. In: White HJ, Smith R, eds. *Proceedings of the third annual meeting of the International Society for Experimental Hematology*. Houston: International Society for Experimental Hematology; 1974. p. 44-6.
10. Bieber MM, Kaplan HS. T-cell inhibitor in the sera of untreated patients with Hodgkin's disease [Abstract]. Paper presented at the International Conference on Malignant Lymphoma Current Status and Prospects, Lugano, 1981:15.
11. Worwood M. Serum ferritin. In: Cook JD, ed. *Iron*. New York: Churchill Livingstone; 1980. p. 59-89. (Chanarin I, Beutler E, Brown EB, Jacobs A, eds. *Methods in hematology*; vol 1).
12. Ranofsky AL. *Surgical operation in short-stay hospitals: United States-1975*. Hyattsville, Maryland: National Center for Health Statistics; 1978. DHEW publication no. (PHS) 78-1785, (Vital and health statistics; series 13; no. 34).

References to Personal Communications and Unpublished Data should be incorporated in the text and not placed under the numbered References. Please type the references exactly as indicated above and avoid useless punctuation (e.g. periods after the initials of authors' names or journal abbreviations).

Galley Proofs and Reprints. Galley proofs should be corrected and returned by fax or express delivery within 72 hours. Minor corrections or reasonable additions are permitted; however, excessive alterations will be charged to the authors. Papers accepted for publication will be printed without cost. The cost of printing color figures will be communicated upon request. Reprints may be ordered at cost by returning the appropriate form sent by the publisher.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Ferrata Storti Foundation. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

For additional information, the scientific staff of *Haematologica* can be reached through:

mailing address: *Haematologica*, Strada Nuova 134, I-27100 Pavia, Italy. Tel. +39.382.531182. Fax +39.382.27721.

e-mail: haema@telnetwork.it – web: <http://www.medit.it/haematologica>

Haematologica 1997; vol. 82, supplement to no. 5

Contents

(indexed by Current Contents/Life Sciences and in Faxon Finder and Faxon XPRESS, also available on diskette with abstracts)

Symposium IDARUBICIN: NEW PHARMACOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS

Taormina, Italy, October 1997

Chairmen: Prof. Sergio Amadori, Prof. Mario Lazzarino

TABLE OF CONTENTS

- 1 Pharmacology of chronic oral daily administration of idarubicin. *Giuseppe Toffoli, Roberto Sorio, Paola Aita, Diana Crivellari, Giuseppe Corona, Gioia Rimondi, Alessandra Bearz, Franco Stocco, Isabel Robieux, Mauro Boiocchi*
- 4 Low-dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia. *Maurizio Musso, Ferdinando Porretto, Alessandra Crescimanno, Francesca Bondi, Vita Polizzi, Renato Scalone, Manlio Tolomeo, Guglielmo Mariani*
- 9 Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. *Rosangela Invernizzi, Alessandro Pecci, Giuseppe Rossi, Anna Maria Pelizzari, Marcello Giusto, Carmine Tinelli, Edoardo Ascari*
- 13 Idarubicin in induction treatment of acute myeloid leukemia in the elderly. *Franco Leoni, Stefania Ciolli, Chiara Nozzoli, Claudia Marrani, Roberto Caporale, Pierluigi Rossi Ferrini*
- 19 A single high dose of idarubicin combined with high dose ARA-C (MSKCC ALL-3 Protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. *Anna Maria Testi, Maria Luisa Moleti, Fiorina Giona, Luciana Annino, Sabina Chiaretti, Ilaria Del Giudice, Elisabetta Todisco, Giannamaria D'Elia, Antonella Ferrari, William Arcese, Franco Mandelli*
- 23 Idarubicin in low-grade non-Hodgkin's lymphomas. *Pier Luigi Zinzani*

review

Haematologica 1997; 82(suppl. to n. 5):1-3

PHARMACOLOGY OF CHRONIC ORAL DAILY ADMINISTRATION OF IDARUBICIN

GIUSEPPE TOFFOLI,[°] ROBERTO SORIO,* PAOLA AITA,[°] DIANA CRIVELLARI,* GIUSEPPE CORONA,[°] GIOIA RIMONDI,* ALESSANDRA BEARZ,* FRANCO STOCO,[#] ISABEL ROBIEUX,* MAURO BOIOCCHI[°]
Divisions of [°]Experimental Oncology 1 and ^{*}Medical Oncology, Centro di Riferimento Oncologico, Aviano; [#]Pharmacia-Upjohn, Milan; Italy

ABSTRACT

Idarubicin (4-demethoxydaunorubicin) (IDA) is a daunorubicin analogue with substantial activity in hematologic malignancies and solid tumors. Among several reasons, IDA is of interest because of its main metabolite derivative, the C-13 alcohol analogue, idarubicinol (IDOL). Previous studies have suggested that IDOL, unlike other anthracycline metabolic derivatives, possesses a striking growth-inhibitory activity in tumor cell lines. This suggests that IDOL, like IDA could be useful in circumventing MDR. IDA is bioavailable in an oral dosage form. After oral administration of IDA to the patients, the concentration of IDOL quickly exceeds that of IDA and is retained in the plasma for a longer period. Hence, administration of IDA to cancer patients results in a much greater overall exposure of the tumor to IDOL than to the parent compound. At the Oncology Center (CRO) in Aviano we performed a dose-finding and pharmacokinetic (PK) study of chronic daily oral IDA with inpatient escalation in patients with metastatic breast cancer (MBC). All the patients were pretreated with anthracyclines (the cumulative dose was 530 mg and 264 mg, respectively, for epirubicin and DOX) and had at admittance a PS \leq 2 and a left ventricular ejection fraction $>50\%$. IDA

(1 mg capsules) was administered orally twice a day for 21 days every two weeks. Treatment was continued at escalating doses until progression or intolerance. Twenty-five patients were enrolled. MTD has not yet been reached and clinical results are reported in Table 1. Treatment was well-tolerated in all but one patient (300 ANC at day 28). Three patients had tox G3 ANC for more than three weeks after 3, 6, and 7 mg doses, respectively. Two of them stopped chemotherapy after 1 cycle and 1 patient stopped after 2 cycles (6 mg doses). Despite previous treatments with anthracyclines (the mean cumulative dose before entering the study was 530 and 264 mg, respectively, for epirubicin and DOX) no cardiotoxicity due to IDA treatment was observed. This trial demonstrates the feasibility of chronic daily IDA administration. At the dosage reported, treatment was generally well tolerated. The PK findings (high IDOL concentrations) and the unexpected G4 myelotoxicity in patients with the highest IDOL plasma concentrations suggest that IDOL is clinically relevant.

Key words: chemotherapy, idarubicin, idarubicinol, oral administration

Anthracyclines have proven to be among the most effective drugs in the therapy of malignant diseases. However, their clinical use is restricted by acute bone marrow toxicity and chronic cumulative cardiotoxicity; moreover, the development of drug resistance is an important factor limiting the use of anthracyclines.¹ A number of analogs of daunorubicin (DAU) and its 14-hydroxy derivative, doxorubicin (DOX), have been synthesized with the aim of reducing side effects and overcoming drug resistance to anthracyclines.

Idarubicin (4-demethoxydaunorubicin) (IDA) is a

DAU analog with substantial activity in hematologic malignancies and solid tumors.² The therapeutic index of IDA in experimental animals and its clinical efficacy in acute myelogenous leukemia are more favorable than DAU,^{3,4} probably because of its pharmacological characteristics and intracellular action mechanism. IDA has greater growth inhibitory activity in experimental human tumors,⁵ possesses superior activity in DNA damage,⁶ and is less cardiotoxic than DAU.⁷ *In vitro* studies indicate that it is more effective than the parent compound in tumor cell lines with the multidrug resistant

(MDR) phenotype.^{8,9} We previously demonstrated that in MDR LoVo human cell lines, the P-glycoprotein (P-gp) localized in the subcellular structures affected DAU, but not IDA nuclear/cytoplasmic distribution; this may explain why MDR cell lines were less resistant to IDA than to DAU.¹⁰

IDA is of further interest because of its main metabolite derivative, the C-13 alcohol analog, idarubicinol (IDOL). Conversion of anthracyclines to their alcohol metabolites via ketoreductase metabolism is generally regarded as an inactivation pathway on the basis of the relatively lower activity of the corresponding alcohol metabolites. Previous studies have suggested that IDOL, unlike other anthracycline metabolic derivatives, possesses a striking growth inhibitory activity in tumor cell lines.¹¹ Moreover, IDOL is effective in MDR cell lines.^{12,13} This suggests that IDOL, like IDA could be useful in circumventing MDR.

IDA is bioavailable in an oral dosage form. After oral administration of IDA to the patients, the concentration of IDOL quickly exceeds that of IDA and is retained in the plasma for a longer period.¹⁴ Hence, administration of IDA to cancer patients results in a much greater overall exposure of the tumor to IDOL than to the parent compound. There are several advantages to an oral dosage form. Currently, anthracyclines must be administered by the i.v. route, which requires an office, hospital, or clinical visit. An oral dosage form would improve the ease of administration, eliminate the costs associated with i.v. therapy, eliminate the potential for tissue damage from drug extravasation, and possibly improve patient compliance. However, there is another important aspect deriving from the use of oral IDA, i.e., the possibility of investigating new schedules for this drug. There is now a growing interest in the use of prolonged infusion schedules or chronic daily administration rather than single dose regimens¹⁵ as a possible way to improve the therapeutic index of chemotherapy. One simple pharmacokinetic goal of this approach would be the reduction of potentially toxic peak concentrations while maintaining the overall drug exposure (i.e., the area under the curve of plasma concentration versus time; AUC or $C \times T$). Moreover, the degree of resistance tends to be lower with continuous vs drug exposure in model systems.¹⁶ The high half-life of IDA (10-33 h) and its active metabolite IDOL (36-64 h) are favorable features for an oral chronic daily administration of the drug since these pharmacokinetic characteristics avoid sways in plasma drug concentrations, thus simulating a prolonged i.v. infusion and allowing tumor cells to be continuously exposed to the drug.

At the Oncology Center (CRO) in Aviano we performed a dose-finding and pharmacokinetic (PK) study of chronic daily oral IDA with inpatient

escalation in patients with metastatic breast cancer (MBC). All the patients were pretreated with anthracyclines (cumulative dose was 530 mg and 264 mg, respectively, for epirubicin and DOX) and had at admittance a PS ≤ 2 and a left ventricular ejection fraction $>50\%$. IDA (1 mg capsules) was administered orally twice a day for 21 days every two weeks. Treatment was continued at escalating doses until progression or intolerance. If hematologic toxicity grade 0, 1, or 2 was observed, the dose was escalated by 1 mg step; for G3 toxicity, the same dose was to be continued. The maximum tolerated dose (MTD) was defined as 2 episodes of G4 hematological toxicity, or febrile neutropenia, or G3 hematological toxicity.

IDA and IDOL were measured in plasma by HPLC and PK was studied at steady state using non-compartmental equations.

Twenty-five patients were enrolled. The maximum tolerated dose of MTD has not been yet reached and clinical results are reported in Table 1. Treatment was well-tolerated in all but one patient (300 ANC at day 28). Three patients had toxicity G3 ANC for more than three weeks after 3, 6, and 7 mg doses, respectively. Two of them stopped chemotherapy after 1 cycle and 1 patient stopped after 2 cycles (6 mg doses). Despite previous treatments with anthracyclines (the mean cumulative dose before entering the study was 530 and 264 mg, respectively, for epirubicin and DOX), no cardiotoxicity due to IDA treatment was observed. The patient who had G4 neutropenia also had a peculiar PK profile with a very high systemic exposure to IDOL [6.7 times higher than that of other patients at the same dose level ($p < 0.01$)].

PK results were: half-life 21 ± 11 hr, and 45 ± 18 hr for IDA and IDOL, respectively; apparent systemic clearance was 598 ± 311 L/hr for IDA and 83 ± 38 L/h for IDOL. IDA distribution volume ($V_{d_{app}}IDA$) was 15400 ± 5350 L and $V_{d_{app}}IDOL$ was 5100 ± 2600 L. Mean IDOL/IDA ratio was 11.

In conclusion, this trial demonstrates the feasibility of chronic daily IDA administration. At the dosage reported, treatment was generally well toler-

Table 1. Escalating doses and hematological toxicity (# pts - WHO grade neutropenia).

	Daily dose							
	2 mg	3 mg	4 mg	5 mg	6 mg	7 mg	8 mg	9 mg
# new (total) pts	7 (7)	4 (9)	1 (6)	4 (6)	3 (7)	5 (9)	1 (4)	0 (2)
Toxicity	7 (G0)	1 (G4)	1 (G2)	1 (G2)	2 (G3)	3 (G3)	1 (G3)	1 (G3)
# cycles with PK	7	9	6	4	11	9	4	2

Pts, patients; PK, pharmacokinetics.

ated. The PK findings (high IDOL concentrations) and the unexpected G4 myelotoxicity in patients with the highest IDOL plasma concentrations suggest that IDOL is clinically relevant.

References

1. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. *Drugs* 1994; 47:223-58.
2. Cersosimo RJ. Idarubicin: an anthracycline antineoplastic agent. *Clin Pharmacol* 1992; 11:152-67.
3. Casazza AM, Di Marco A, Bonadonna G. Effects of modifications in position 4 of the chromophore or in position 4' of the aminosugar on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Crooke ST, Reich SD, eds. *Anthracyclines. Current status and new developments*. New York: Academic Press; 1980. p. 403-30.
4. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? *Haematologica* 1995; 80:82-90.
5. Fukushima T, Ueda T, Uchida M, Nakamura T. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. *Int J Hematol* 1993; 57:121-30.
6. Capranico G, Riva A, Tinelli S, Dasdia T, Zunino F. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. *Cancer Res* 1987; 47:3752-6.
7. Bertelli G, Amoroso D, Pronzato P, Rosso R. Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors. *Anticancer Res* 1988; 8:645-6.
8. Facchetti I, Grandi M, Cucchi P, Geroni C, Penco S, Vigevani A. Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. *Anti-Cancer Drug Des* 1991; 6:385-97.
9. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. *Blood* 1992; 79:3267-73.
10. Toffoli G, Simone F, Gigante M, Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. *Biochem Pharmacol* 1994; 48:1871-81.
11. Ames MM, Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. *Leukemia* 1992; 6:70-5.
12. Kuffel MJ, Ames MM. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. *Cancer Chemother Pharmacol* 1995; 36:223-6.
13. Toffoli G, Corona G, Simone F, Gigante M, De Angeli S, Boiocchi M. Cellular pharmacology of idarubicinol in multidrug LoVo Cell lines. *Int J Cancer* 1996; 67:129-37.
14. Camaggi CM, Strocchi E, Carisi P, et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. *Cancer Chemother Pharmacol* 1992; 30:307-16.
15. Einhorn LH. Daily oral etoposide in the treatment of cancer. *Semin Oncol* 1991; 18:43-7.
16. Lai GM, Chen Y-N, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. *Int J Cancer* 1991; 49:696-703.



LOW-DOSE LONG-TERM ORAL IDARUBICIN IN MAINTENANCE TREATMENT OF ELDERLY ACUTE MYELOID LEUKEMIA

MAURIZIO MUSSO, FERDINANDO PORRETTO, ALESSANDRA CRESCIMANNO, FRANCESCA BONDÌ, VITA POLIZZI, RENATO SCALONE, MANLIO TOLOMEO, GUGLIELMO MARIANI

Cattedra Divisione di Ematologia con Trapianto di Midollo, Università di Palermo, Italy

ABSTRACT

Background and Objective. Low-dose long-term oral IDA may play a role in maintenance treatment of elderly patients with AML; in fact, continuous exposure to IDA and IDAol could be efficacious in the disease control possibly inducing cell-differentiation and/or apoptosis.

Methods. We enrolled 25 previous responder patients in standard induction therapy to receive maintenance oral IDA 5 mg daily on days 1-14 at 2-week intervals for at least 6 months. We also evaluated the cell-cycle and apoptosis in leukemic cells from patients after IDA administration and, as a control, from HL60 lines exposed to IDA and IDAol *in vitro*.

Results. Long-term low-dose IDA was well-tolerated. Neutrophil and platelet count never below under $1 \times 10^9/L$ and $50 \times 10^9/L$ respectively in CR

patients, and no infectious complications were encountered. Non-hematological toxicity was also acceptable: easily controlled nausea and vomiting, non-recorded diarrhea or mucositis were reported. The convenience of oral administration contributed to excellent compliance. DNA analysis performed *in vivo* after IDA and IDAol exposure showed an increase of G₂/M cell frequencies and evidence of sub-G₁ peak.

Interpretation and Conclusions. In conclusion, long-term low doses of oral IDA would appear valuable as a maintenance regimen for elderly patients. Our results seem to confirm the preliminary hypothesis that IDA + IDAol induce an increase of apoptosis in leukemic cells.

Key words: elderly, AML, idarubicin, apoptosis

Acute myeloid leukemia (AML) is seen at all ages, however, more than half of the patients with AML are over 60 years old.^{1,2} Despite the increase of AML with age, the optimum regimen for elderly patients is still undefined; in fact, modern therapeutic approaches do not significantly benefit these patients. Over 65% of adults of under 60 years of age achieve complete remission (CR), and survival rates of 35% are commonly obtained, while only 50% of older patients obtain a CR with chemotherapy and only 10% of them have a disease-free survival of beyond 4 years after diagnosis.³ The reason for unsatisfactory results is associated with the underlying biology of AML in older patients, the adverse cytogenetic characteristics, prior myelodysplasia, phenotypic features, MDR1 over-expression, and BCL-2 positivity.⁴⁻⁷

These considerations represent the rationale for offering new therapeutic approaches to older patients with AML. The choice of treatment for elderly patients depends on the balance of the toxicity and the quality of life. Increased treatment-related toxicity complicates chemotherapy, therefore most studies on AML in the elderly suggest a less intensive induction therapy to reduce toxicity.⁸

However, a large fraction of AML patients achieve CR relapse; this disease progression depends on two factors: acquired tumor cell drug resistance and tumor re-growth.⁹ Recently, Shiller *et al.* reported a longer leukemia-free survival in patients treated with high dose ARA-C and autologous stem cell transplantation than in those treated with standard doses.¹⁰

On the other hand, maintenance treatment could play a role in elderly patients with AML, considering that they often cannot be treated with an intensive first line therapy. The choice of post-induction therapy should be a balance between control of leukemia and quality of life.

Idarubicin (IDA), which can be administered orally, is an active anthracycline in AML. Its metabolite, idarubicinol (IDAol), is also active and is formed in much larger amounts after oral administration. Patients over 60 seem to have an impaired IDAol elimination, so that the exposure to IDAol is prolonged in comparison to younger patients treated at the same dosage.¹¹

Oral IDA could play a role in maintenance treatment of elderly patients at low doses and for long-term therapy. In fact, continuous exposure to IDA

and idarubicinol could be efficacious in disease control because of its effects on low-rate proliferation residual leukemic cells, induce an apoptotic cell death, beside a minor dependence of IDA/IDAol on multidrug resistance-mediated MDR1 genes.

On this basis, we have evaluated the feasibility of oral administration of Idarubicin at the dose of 3 mg/m²/day for 14 days consecutively every 4 weeks up to disease progression in elderly AML patients in complete or partial remission after the first conventional scheduled therapy containing ARA-C+VP16+ IDA/Mitox. Moreover, we have studied the apoptosis responses to this therapeutic agent *in vitro* and *in vivo* in myeloid cells collected from patients in partial remission.

Materials and Methods

Twenty-five elderly patients with myeloid leukemia, 5 of them with secondary AML to myeloid dysplastic syndrome, with a median age of 70 years (range 60-83), M/F ratio 17/8, responsive to first line treatment, 8 in CR and 17 in PR, were enrolled in this study (Table 1).

Induction and consolidation treatment consisted of ARA-C 100 mg/m² × 5 days-VP16 100 mg/m² × 3 days and IDA or Mitox at a dosage of 8 mg/m² and 12 mg/m², respectively, for 3 days; response to therapy was assessed according to the *Cancer and Leukemia B Group Criteria*.¹²

The maintenance treatment consisted of oral IDA 3 mg/m²/day for 14 days every 4 weeks until relapse or disease progression occurred.

Fresh and frozen cells samples were obtained from all elderly patients included in this study at 3 different times: before beginning IDA administration, during treatment at the 7th day and at the 14th day for the studies *in vivo*. As an *in vitro* control we used cell line HL60. These samples were Ficoll purified and contained approximately 1 × 10⁷ cells each; part of the cells were used for cytogenetic analysis.

Ficoll-separated cells were suspended at a concentration of 2 × 10⁶/mL in minimal essential medium (MEM) supplemented with 20% FCS and cultured for 16-18 hours in plastic flasks at 37°C in a humidified atmosphere containing 5% CO₂, with IDA at the dosage of 0.001 µg/mL and or with IDAol at the dosage of 0.0012 µg/mL corresponding to the concentration of 1 ng/mL *in vivo*.

They were assayed for cell-cycle and apoptosis at 16-20 hours post-treatment.

These cells were incubated with propidium iodide for DNA stain for 30 minutes and analyzed by cytometric assay with the FACScan by CellFIT program (BD); 10.000-50.000 cells of each sample were analyzed: cells frequencies in cell-cycle compartments are expressed as percentage of the number within the complete cell-cycle.

Apoptosis cell frequencies are expressed as per-

Table 1. Clinical and biological characteristics of elderly patients with AML.

	CR	PR
N. of patients	8	17
Median age	66	74
Range	60-70	60-83
Sex M/F	6/2	11/6
FAB		
M0	1	1
M1	2	5
M2	4	7
M4	1	4
Secondary	2	3
Hepatomegaly	1	8
LDH U/L		
median	408	441
range	275-683	382-1238
Favorable karyotype	5	3
Adverse karyotype	—	6

Table 2. Hematological toxicity in a) and transfusional requirement in b) in patients in CR and PR.

a)	CR		PR	
	n° pts	WHO	n° pts	WHO
WBC	3-8	1-2	10/17	1-3
Hb	3-8	1	12/17	2-4
PLT	2/8	2	12/17	1-4
b)		CR		PR
RBC Units		—		2 (0-4)
PLT Units		—		12 (0-16)

centage of the total cell number.

Cells with sub-G₁ DNA content were scored as apoptotic according to previous studies.⁶

Drugs effects on apoptosis and necrosis were determined morphologically by fluorescent microscopy after labelling with acridine orange and ethidium bromide as described by Duke and Cohen.¹³

Surface markers were analyzed by flow cytometry as previously described with antibodies of the following specificities: CD13, CD14, CD15, CD33, CD34; while BCL-2 expression was analysed using the antihuman BCL-2 clone antiserum (DAKO) after permeabilization by Permeaphix (Ortho). The staining was considered positive when 20% more cells than in the control were stained.

Table 3. Hematological toxicity in a) and transfusional requirement in b) in patients in CR and PR.

	CR		PR	
	n° pts	WHO	n° pts	WHO
Alopecia	8	0	17	0
Cardiac	8	0	17	0
Hepatic	8	0	17	0
Nausea/vomiting	1	1	3	2
Diarrhea	8	0	17	0

Table 4. Results in a) patients in complete remission; in b) patients in partial remission.

a)	Disease-Free Survival	Overall Survival
Median	8	13.5
Range	4-16	5-40
b)	Progression-Free Survival	Overall Survival
Median	5	8.5
Range	3-19	3-24

Results

In CR patients, only mild to moderate hematological toxicity was registered (Tables 2 and 3).

No transfusion requirement occurred in CR patients while in PR patients, a median of 2 U of RBC and 12 U of PLT were transfused. No major bleeding or documented infection occurred.




Mild nausea and vomiting that were easily controlled were noted in 3 PR patients.

Table 4 shows the clinical results. In patients in CR, DFS and OS were 8 and 13.5 months, respectively; OS and PFS in those patients in PR were 5 and 8.5 months, respectively. DNA analysis showed a sub G₁ peak both *in vivo* (only in patients with PR) and in *in vitro* samples. Moreover, we observed an increase in G₂+M cell frequencies (Figures 1-6). An apoptotic morphology assay confirmed these results. For all patients in PR, the leukemic cells were BCL-2 positive, furthermore, no change of BCL-2 expression emerged during treatment.

Discussion

Age is a major adverse prognostic factor in AML in elderly patients, both in the achievement of CR and OS, because these patients frequently have a poor performance status and other biological features such as hepatomegaly, elevated serum urea and the presence of cytogenetic abnormalities.¹⁴

In fact, only 10% of patients will survive free of leukemia beyond 4 years after diagnosis. The choice

**Figure 1. DNA analysis of HL60 cells after 24-hour culture (control) showing a G₂+M cell frequencies of 5.5%.****Figure 2. DNA analysis of HL60 cells after 24-hour exposure to IDA/IDAol, showing a sub-G₁ peak (13.4%), and an increase of G₂+M cell frequencies (48%).****Figure 3. DNA analysis of HL60 cells after 48-hours culture (control) showing a G₂+M cell frequencies of 14.9%.**




Figure 4. DNA analysis of HL60 cells after 48-hour culture with IDA/IDAol, showing a sub-G1 peak (26.2%), and a G₂+M cell frequencies of 28.8%.




Figure 5. DNA analysis at day 0 of leukemia cells showing a G₂+M cell frequencies of 6.5%.

of treatment for elderly patients depends on the balance between toxicity and quality of life. Most studies about AML in patients over 60 suggest less intensive induction therapy to reduce toxicity. Moreover, a large percentage of patients who achieve a CR have a relapse. Maintenance treatment could play an important role in these patients who often cannot be treated with an intensive first-line therapy. In fact, the post-induction therapy by continuous administration of low doses of IDA for a long term should warrant a control of the residual leukemic cells (inducing an apoptotic cell death). Recently, studies by cytometric assay report a variable response to treatment-induced apoptotic AML cells after exposure to several drugs (ARA-C, DNR).⁹

Our results show an increase in apoptosis in the leukemic cells after IDA and IDAol *in vitro* and *in vivo* exposure only in those samples exposed to IDA and




Figure 6. DNA analysis at day 7 of leukemia cells from patients treated with IDA 3 mg/m²/d showing an increase of G₂+M cell frequencies (42%) and a sub-G1 peak of 17.8%. Similar results were found at day 14 analysis.

IDAol at the same time. Moreover, we observed an increase in G₂+M cell frequencies (Figures 1-6).

On the other hand, Ara-C gives similar results, while only an increase of G₂+M cell frequencies is reported after DNR exposure.⁹

Regarding the BCL-2 positive cells and the prospective apoptosis correlation, we found over-expression in many AML cells of patients in PR, yet these were correlated to treatment-induced apoptosis frequencies. Furthermore, only cells from PR patients showed high BCL-2 positive cells, suggesting that tumor drug resistance was more frequent in these cases. Our clinical results showed a very low hematological and extrahematological toxicity, and a good compliance with this schedule of treatment. The preliminary biological study results seem to confirm the hypothesis that long term exposure to low doses of IDA induces increase of apoptosis in leukemic cells.

In conclusion, long-term low dose oral IDA could represent a choice for maintenance treatment of elderly AML patients in CR, even if more extensive and randomized trials are necessary for evaluating the impact of DSF and OS.

References

1. Brinker H. Estimate of overall treatment results in acute non lymphocytic leukemia based on age-specific rates of incidence and of complete remission. *Cancer Treat Rep* 1985; 69:5-11.
2. Cartwright RA, Staines A. Acute leukemias. *Epidemiology of Haematological Disease*. I. Fleming AT, ed. Baillière Clin Haematol 1992; 5:1-26.
3. Lowenberg B. Acute myelogenous leukaemia and myelodysplasia. *Baillière Clin Haematol* 1996; 9:147-59.
4. Keating MJ, McCredie KB, Benjamin RS, et al. Treatment of patients over 50 years of age with myelogenous leukemia with a combination of rubidazole and cytosine arabinoside, vincristine and prednisolone (ROAP). *Blood* 1981; 58:584-91.
5. Swirsky DM, De Bastos M, Parish SE, Rees JKH, Hayhoe FGJ. Features affecting outcome during remission induction of acute

- myeloid leukemia in 619 adult patients. *Br J Haematol* 1987; 64:435-53.
6. Campos L, Roualt JP, Oriol P, et al. High expression of BCL-2 protein in acute myelogenous leukemia cells is associated with poor response to chemotherapy. *Blood* 1993; 81:3091-6.
 7. Liu Yin JA. Acute myeloid leukemia in elderly: biology and treatment. *Br J Haematol* 1993; 8:361-6.
 8. Baudard M, Marie JP, Cadiou M, Viguié V, Zittoun R. Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. *Br J Haematol* 1994; 86:82-91.
 9. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis. *Blood* 1997; 89:243-55.
 10. Shiller JC. Post-remission therapy of acute myeloid leukemia in older adults. *Leukemia* 1996; 10(Suppl.1):S18-S20.
 11. Leoni F, Ciolli S, Pascarella A, et al. Attenuated-dose idarubicin in acute myeloid leukemia of the elderly: pharmacokinetic study and clinical results. *Br J Haematol* 1995; 90:169-74.
 12. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. *Blood* 1968; 32:507.
 13. Duke RC, Cohen JJ. Morphological and biochemical assay of apoptosis. In: Coligan JE, Kruisbeak AM, eds. *Current Protocols in Immunology*. New York: John Wiley & Sons; 1992. p. 3171-6.
 14. Johnson RE, Ryder WDJ, Liu Yin JA. Validation of a model to predict survival in elderly patients with acute myeloid leukemia. *Br J Haematol* 1995; 90:954-6.



IDARUBICIN AND CYTOSINE ARABINOSIDE IN THE INDUCTION AND MAINTENANCE THERAPY OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

ROSANGELA INVERNIZZI, ALESSANDRO PECCI, GIUSEPPE ROSSI,* ANNA MARIA PELIZZARI,*

MARCELLO GIUSTO, CARMINE TINELLI,^o EDOARDO ASCARI

Medicina Interna ed Oncologia Medica, Università di Pavia e ^oUnità di Biometria, IRCCS Policlinico S. Matteo, Pavia; *Sezione di Ematologia, Spedali Civili, Brescia, Italy

ABSTRACT

Background and Objective. Recently, the results of a few pilot studies have shown the efficacy of the association of idarubicin (IDA) and cytosine arabinoside (Ara-C), already successfully employed in acute myeloid leukemia (AML), for remission induction in patients with myelodysplastic syndrome (MDS). We set out to evaluate in a multicenter study the efficacy and tolerability of an intensive therapy with IDA and Ara-C in patients with RAEB and RAEB-t, the rate and duration of CR and the overall survival in adults treated with full doses and in the elderly treated with lower doses; furthermore, we investigated the efficacy of low-dose maintenance chemotherapy.

Methods. Pretreated adult patients with *de novo* RAEB and RAEB-t, meeting at least one of the following criteria, were included: neutrophils $< 0.5 \times 10^9/L$ or moderate neutropenia with infectious episodes, platelets $< 30 \times 10^9/L$ or moderate thrombocytopenia but with bleeding symptoms, transfusion > 4 red cell units/months, rapid increase of bone marrow blasts. Induction treatment consisted of a cycle with IDA and Ara-C. Adult patients less than 65 years old were treated with the following doses: Ara-C 1 g/m²/day i.v. 6-hour infusion, on days 1-4, IDA 10 mg/m²/day i.v., on days 1-3.

Elderly patients (≥ 65 yrs) were treated with lower doses: Ara-C 1 g/m²/day 6 hours infusion, on days 1 and 2, IDA 10 mg/m²/day i.v., on days 1 and 2. Responders followed a consolidation course identical to induction.

Results. From February 1994 to February 1997, 25 patients were enrolled, 20 males and 5 females aged between 22 and 76, 10 were ≥ 65 years old, 7 had RAEB and 18 had RAEB-t. Twelve cases (48%) achieved complete remission (CR), 7 cases (28%) achieved partial remission, 4 patients were resistant and two patients (8%) died during the aplastic phase. A significantly higher CR rate was found in younger patients ($p = 0.036$), while gender, FAB subtype, presence of Auer rods, cytogenetic findings, and the interval from diagnosis to treatment did not significantly influence CR achievement.

Interpretation and Conclusions. Our results show that in *de novo* RAEB and RAEB-t, the employed treatment with IDA and Ara-C is associated with satisfactory frequency of response with acceptable toxicity.

Key words: acute myeloid leukemia, chemotherapy, idarubicin, cytosine arabinoside

Prognosis in patients with myelodysplastic syndrome (MDS) and a high percentage of bone marrow blasts is very poor: according to the reports of the largest numbers of cases published in the last decade, median survival rates of patients with refractory anemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-t) are 13 and 6 months, respectively.¹

Lack of randomized clinical trials does not allow for the definition of guidelines for therapy of RAEB and RAEB-t; furthermore, the relative efficacy of the various treatment approaches is not clear, nor are their advantages in comparison with supportive therapy alone. The only strategy capable of prolonging survival significantly is allogeneic or autolo-

gous bone marrow transplantation.² For patients aged between 55 and 65, intensive chemotherapy is the most efficacious treatment. In fact, complete remission (CR) can be reached in about 60% of cases; it lasts, however, only about 10 months and less than 10% of cases are disease-free at 3 years.^{3,4}

Recently, the results of a few pilot studies have shown the efficacy of the association of idarubicin (IDA) and cytosine arabinoside (Ara-C), already successfully employed in acute myeloid leukemia (AML), for remission induction in patients with MDS.⁵⁻⁹ The lower cardiotoxicity of IDA compared to other anthracyclines, and a reduction of Ara-C doses made the treatment feasible and well tolerated even in elderly patients.

We set out to evaluate in a multicenter study the efficacy and tolerability of an intensive therapy with IDA and Ara-C in patients with RAEB and RAEB-t, the rate and duration of CR and the overall survival in adults treated with full doses and in the elderly treated with lower doses; furthermore, we investigated the efficacy of low-dose maintenance chemotherapy.

Patients and Methods

Patients

Pretreated adult patients with *de novo* RAEB and RAEB-t meeting at least one of the following criteria, were included: neutrophils $<0.5 \times 10^9/L$ or moderate neutropenia with infectious episodes, platelets $< 30 \times 10^9$ or moderate thrombocytopenia but with bleeding symptoms, transfusion > 4 red cell units/months, rapid increase of bone marrow blasts.

Criteria for exclusion were the following: presence of documented infection, asymptomatic disease with stable hematological values, performance status > 2 according to the WHO scale, severe heart failure and/or severe arrhythmias, inadequate liver or renal function, and patients already treated by intensive chemotherapy and/or radiotherapy for previous neoplasms.

Informed consent was obtained from all patients.

Design of the protocol

Induction treatment consisted of a cycle with IDA and Ara-C; adult patients less than 65 years old were treated with the following doses: Ara-C 1 g/m²/day i.v. 6-hour infusion, on days 1-4, IDA 10 mg/m²/day i.v., on days 1-3; elderly patients (≥ 65 yrs) were treated with lower doses: Ara-C 1 g/m²/day i.v. 6-hour infusion, on days 1, 2, IDA 10 mg/m²/day i.v., on days 1 and 2. Responders followed a consolidation course identical to induction. Patients in CR after consolidation regimen had to be treated for 2 years with maintenance therapy consisting of alternate cycles of Ara-C 10 mg/m² s.c. every 12 hours for 10 days a month, and IDA 15 mg/m²/day p.o. for 3 days a month.

Complete remission was defined as normocellular bone marrow with less than 5% blasts and at least $1.0 \times 10^9/L$ neutrophils and $100 \times 10^9/L$ platelets in the peripheral blood. Partial remission (PR) was defined as a 50% or more reduction of blasts in a normocellular marrow.

Statistics

Actuarial curves were calculated according to the method of Kaplan-Meier. The differences between curves were statistically tested using the two-tailed log-rank test. Comparisons of some parameters for their prognostic value were performed with the Fisher exact test. The duration of survival was calcu-

Table 1. Characteristics of the patients.

Total patients	25
M/F	20/5
Age	
<i>median (range)</i>	61 (22-76)
≥ 65 yrs	10
AREB/AREB-t	7/18
Interval from diagnosis	
< 3 months	20
≥ 3 months	5
Karyotype	
<i>normal</i>	9
<i>abnormal</i>	12
Hb g/L	
<i>median (range)</i>	8.8 (4.5-12.8)
Neutrophils $\times 10^9/L$	
<i>median (range)</i>	0.95 (0.01-6.49)
Platelets $\times 10^9/L$	
<i>median (range)</i>	46 (8-260)

Table 2. Response to therapy.

	Total	< 65 years	(≥ 65 years)
Patients	25	15	10
Complete remission	12 (48%)	10 (67%)	2 (20%)
Partial remission	7 (28%)	2 (13%)	5 (50%)
No remission			
Death in aplasia	2 (8%)	1 (7%)	1 (10%)
Resistant	4 (16%)	2 (13%)	2 (20%)
Median survival (months)	12	21	5

lated from the date of starting of treatment until death. For patients who achieved CR, the disease-free survival (DFS) was calculated from the date of first CR to the date of relapse, death in CR or the most recent follow-up.

Results

From February 1994 to February 1997, 25 patients were enrolled, 20 males and 5 females aged between 22 and 76, 10 were ≥ 65 years old, 7 had RAEB and 18 had RAEB-t. Their clinical and hematological features are summarized in Table 1. In 5 cases, treatment was started more than 3 months after diagnosis.

Twelve cases (48%), 2 RAEB and 10 RAEB-t, ≥ 65 years old achieved CR; 7 cases (28%), 5 ≥ 65 years old achieved PR; 4 patients (16%), 2 ≥ 65 years old were resistant to therapy (Table 2). A significantly higher CR rate was found in younger patients ($p=0.036$), while gender, FAB subtype,

Table 3. Toxicity of chemotherapy (> grade 1 WHO).

	Induction course	Consolidation course	Maintenance course
No. of evaluable cases	25	18	11
Infection/FUO	11/13	3/5	0/2
Hemorrhage	9	6	0
Gastrointestinal	5	2	0
Hepatic	2	2	1
Cardiovascular	3	1	0
Alopecia	9	5	1

Table 4. Supportive therapy.

	Induction course	Consolidation course
Platelets units (mean±se)		
Apheresis	3.1±1.6	1.2±0.7
Random	20.5±8.4	11.5±3.8
Erythrocyte unit (mean±se)	9.4±1.7	8.0±1.9

presence of Auer rods, cytogenetic findings, and the interval from diagnosis to treatment did not significantly influence CR achievement. Two patients (8%) died during the aplastic phase, one from sepsis and one from cerebral hemorrhage, aged 57 and 66, respectively. Complications of chemotherapy as well as supportive therapy are summarized in Tables 3 and 4.

Among CR patients, median times to recovery of neutrophils ($1 \times 10^9/L$) and platelets ($100 \times 10^9/L$) were, respectively, 21 (range 16-24) and 18 (range 14-28) days. No severe complications occurred during consolidation and maintenance courses.

The median duration of DFS was 18 months. The median survival duration of patients achieving CR was 21 months, while it was only 5 months in the PR and resistant patients ($p=0.002$); median survival for the whole population was 12 months (Figure 1). Survival duration was significantly ($p=0.043$) longer in patients with normal karyotypes (median 21 months) compared to patients with cytogenetic anomalies (median 11 months). Eight patients are still living, 7 of whom are in continuous CR that has lasted for more than 19 months in 3 cases.

Discussion

Since the early eighties, according to the schedules commonly used for acute leukemia, intensive chemotherapy has been employed for the treatment of high risk MDS, with the aim of eradicating the pathological clone, allowing for the recovery of normal hematopoiesis.^{10,11} Lack of randomized trials, however, does not yet allow for the evaluation of the real efficacy of this kind of treatment, nor of its advantages in comparison with supportive therapy alone. Furthermore, the interpretation of the results of the studies already published is difficult for other reasons: groups of patients are small, FAB subtype is not specified, both primary and secondary cases, almost always in leukemic progression as well, are included.^{3,4}




Figure 1. Actuarial survival curves of all patients, of patients achieving CR and of patients not achieving CR.

Generally, combinations of anthracyclines and Ara-C at standard or high doses, with or without thioguanine, have been used.^{5,6,8,12-14} CR rates were variable, ranging from 15% to 80%, but they were usually lower than in *de novo* acute leukemia.^{7,8,11,14,15} The most important reasons for this phenomenon are the generally older age of patients with MDS, as well as peculiar biological characteristics of the dysplastic clone, namely, the increased expression of chemoresistance proteins and the higher incidence of complex cytogenetic anomalies.^{16,17} In fact, if such prognostic factors are matched, the results of treatment are similar in *de novo* AML and in MDS.¹⁷

Cytopenias are long with high incidence of toxic deaths (14-25%), generally due to infections. The duration of remission as well as survival, ranging respectively from 6 to 12 months and from 9 to 18 months, is shorter than in *de novo* AML.^{8,10,14,18,19}

We performed a prospective multicenter study of intensive chemotherapy for patients with RAEB and RAEB-t, in good clinical conditions, with serious or symptomatic cytopenia. Our protocol consisted of induction and consolidation regimens with IDA and Ara-C and of maintenance cycles with the same drugs at low doses. Idarubicin was used in consideration of its lower cardiotoxicity compared to other anthracyclines, and of its previous documented efficacy against blasts expressing high drug resistance.

Our results show that in *de novo* RAEB and RAEB-t, this combination regimen is associated with a satisfactory frequency of response with acceptable toxicity. In fact, 76% of our patients achieved CR or PR, while the therapy-related mortality was rather low. Only a complete response, however, significantly influenced the duration of survival. These data support the results of other recent studies;^{8,14,18,19} in patients less than 65 years old, the CR rate (67%) reported by us was even higher than those described by other authors using similar regimens, but excluding elderly patients. Therefore, intensive chemotherapy is certainly indicated in young patients with high risk MDS, although these are only a minority of the whole MDS patient population.²⁰ Probably, the use of full dose therapy in the elderly as well may increase their rather low CR rate, since no other prognostic factors were found to influence the achievement of remission.

Finally, although the short follow-up period does not allow for definitive conclusions, the fact that the CR duration of our patients was slightly longer than those reported by other authors suggests that maintenance therapy may prolong the period of CR and survival. It remains to be seen whether autologous stem cell transplantation can improve the out-

come of CR in MDS patients as it does in AML patients.²¹ A limiting factor for this procedure, however, might be a low number of normal residual stem cells.

References

- Gallagher A, Darley RL, Padua R. The molecular basis of myelodysplastic syndromes. *Haematologica* 1997; 82:191-204.
- Aglietta M, De Vincentiis A, Lanata L, et al. Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. *Haematologica* 1996; 81:77-92.
- Cheson BD. Chemotherapy and bone marrow transplantation for myelodysplastic syndromes. *Semin Oncol* 1992; 19:85-94.
- Gassmann W, Schmitz N, Loeffler H, De Witte T. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. *Semin Hematol* 1996; 33:196-205.
- Ganser A, Heil G, Kolbe K, et al. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia. *Ann Hematol* 1993; 66:123-5.
- Hoffmann K, Flasshove M, Fricke HJ, et al. Therapy of advanced myelodysplastic syndrome (MDS) with cytarabine and idarubicin (AIDA). *Proc Am Soc Clin Oncol* 1995; 14:335.
- Estey EH, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. *Semin Oncol* 1993; 20 (suppl 8):1-5.
- De Witte T, Suciu S, Peetermans M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). *Leukemia* 1995; 9:1805-11.
- Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? *Haematologica* 1995; 80:82-90.
- Mertelsmann R, Thaler HT, To L, et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. *Blood* 1980; 56:773-81.
- Armitage O, Dick FR, Needleman SW, et al. Effect of chemotherapy for the dysmyelopoietic syndrome. *Cancer Treat Rep* 1981; 65:601-5.
- Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. *J Clin Oncol* 1986; 4:325-45.
- Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. *Br J Haematol* 1986; 63:477-83.
- Fenaux P, Morel P, Rose C, et al. Prognostic factors in adult *de novo* myelodysplastic syndromes treated by intensive chemotherapy. *Br J Haematol* 1991; 77:497-501.
- Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. *J Clin Oncol* 1986; 4:1748-57.
- Lepelletier P, Soenen V, Preudhomme C, Lai JL, Cossou A, Fenaux P. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. *Leukemia* 1994; 8:998-1004.
- Estey E, Pierce S, Kantarjian H, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. *Leuk Lymphoma* 1993; 11 (suppl 2):59-63.
- Economopoulos T, Papageorgiou E, Stathakis N, et al. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). *Leuk Res* 1996; 20:385-90.
- Ruutu T, Hänninen A, Järventie G, et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. *Leuk Res* 1997; 21:133-8.
- Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F. Myelodysplastic syndromes: the pediatric point of view. *Haematologica* 1995; 80:268-79.
- Lambertenghi Delilieri G, Annaloro C, Della Volpe A, et al. Single-institution results of autologous bone marrow transplantation in acute myeloid leukemia. *Haematologica* 1995; 80:136-41.



IDARUBICIN IN INDUCTION TREATMENT OF ACUTE MYELOID LEUKEMIA IN THE ELDERLY

FRANCO LEONI, STEFANIA CIOLLI, CHIARA NOZZOLI, CLAUDIA MARRANI, ROBERTO CAPORALE, PIERLUIGI ROSSI FERRINI

Chair and Department of Hematology, Florence, Italy

ABSTRACT

Background and Objective. The best approach to treatment of acute myeloid leukemia (AML) in elderly patients remains controversial. Intensive chemotherapy is the treatment of choice in selected patients, but age related changes might affect the pharmacokinetics of antineoplastic agents resulting in enhanced toxicity. We report our experience in elderly patients treated with idarubicin at attenuated doses plus cytarabine and etoposide.

Methods. Sixty-six AML patients, median age 66, with progressive disease and high tumor burden received idarubicin 8 mg/sqm i.v. d 1,3,5; cytarabine 200 mg/sqm by continuous i.v. infusion d 1-7; etoposide 60 mg/sqm i.v. d 1-5. A second course with the same drugs was planned irrespective of complete remission (CR) achievement. No consolidation was given; 44% had a documented preexisting myelodysplasia, 45% presented with fever. Promyelocytic leukemias were excluded.

Results. Thirty-five patients (53%) achieved CR

and 9 PR for an overall response rate of 67%. Nine of them (13%) died early or during the aplastic phase. Preexisting myelodysplasia had no significant impact on CR achievement. Resistant disease was associated with CD7 phenotype and unfavorable karyotype. Overall survival and disease free survival were 14 and 13 months, respectively. The major toxicity consisted of infectious complications (WHO > 2 in 24% of patients). Six patients died for infection, 2 for heart failure, 1 for pulmonary embolism.

Interpretation and Conclusions. This induction regimen with attenuated doses of idarubicin is feasible and effective, but long-term survival remains an unresolved problem. Alternative post remission approaches are advisable in the aim of improving the remission duration.

Key words: acute myeloid leukemia, chemotherapy, idarubicin

Since acute myeloid leukemia (AML) in the elderly is intrinsically more chemoresistant,¹ an intensive treatment would be the best choice when toxicity related to intensive chemotherapy can be tolerated. Selecting criteria are needed and treatment should be tailored case by case, according to disease and host related variables. Patients with slowly progressing disease, hypocellular bone marrow or low blast count can as well respond to a low-dose chemotherapy.² In contrast, an aggressive treatment must be applied to AML cases with unfavorable biological characteristics, frequently associated with a multi-drug resistant phenotype. Standard induction treatments are based on cytarabine (ara-C) plus an anthracycline. The availability of the new anthracycline idarubicin (IDA), less involved in multi-drug resistance^{3,4} and superior to daunorubicin in randomized trials would result in better response rate. However, conventional dosages have been regarded as too toxic in the elderly.⁵ We demonstrated that aged patients have an impaired elimination of IDA active metabolite idarubicinol and therefore they should receive IDA at attenuated doses.⁶ Topic

of this report are 66 AML patients aged 60 years or older treated with an induction protocol based on IDA plus ara-C and etoposide.

Patient and Methods

Between January 1992 and December 1996, 140 patients aged sixty or more with previously untreated AML were referred to our Institution. Median age was 67 years (range 60-82). Seven patients with acute promyelocytic leukemia were enrolled in a specific protocol with all-trans retinoic acid. Twenty-two patients presenting with hypoplastic or oligoblastic leukemia were designed to receive three courses of ara-C 20 mg/sqm/d subcutaneously for three weeks (LDara-C). Only supportive care or palliative chemotherapy was delivered to 45 patients due to severe concomitant non hematological disorders or patient's refusal. Sixty-six patients with hypercellular bone marrow or monocytic involvement and rapidly accumulating leukemia related problems were allocated to conventional chemotherapy and are the topic of this report. There was no upper age limit to entry in the

study and patients with AML secondary to a pre-existing myelodysplastic syndrome or myeloproliferative disease (AHD) or to a previous chemo-radiotherapy (t-AML) were eligible. Those presenting with fever due to documented infection, received chemotherapy after a short antibiotic treatment, irrespective of infection resolution. An absolute exclusion criteria was a severe heart failure. Details on the patients clinical characteristics are outlined in Table 1. The diagnosis of AML was defined according to French-American-British (FAB) criteria⁷ and trilineage dysplasia of bone marrow was recorded as proposed by Brito-Babapulle.⁸ Phenotype was determined at diagnosis on bone marrow or peripheral blood specimens by direct immunofluorescence and a FACScan flow cytometer. A wide panel of lineage associated antigens was applied. Determinations were gated and single or double parameters of at least 10.000 cells analyzed. By convention, a case was considered positive if more than 20% of blasts expressed the antigen. Chromosome analysis was performed on bone marrow cells after 24-hour culture. Cells were G-banded with Wright stain and twenty-five metaphases were karyotyped according to the *International System for Human Cytogenetic Nomenclature*.⁹ The karyotypic findings were classified as low-risk (t(8;21), inv16 or t(16;16), del20q, 5q- only) intermediate (normal, +8, 12p abnormality, hypo/hyperdiploid), high risk (complex or >3 abnormalities, -7/7q-).

Induction treatment consisted of two cycles: the first with IDA 8 mg/sqm i.v. on days 1,3 and 5; ara-C 200 mg/sqm by continuous i.v. infusion on days 1-7 and etoposide 60 mg/sqm i.v. on days 1-5; the second was a five-day course at the same schedule but with IDA on days 1 and 3, ara-C and etoposide on days 1-5. Subsequently, patients who achieved partial remission (PR) or complete remission (CR) were designed to receive three 21 days courses of LDara-C as maintenance therapy.

CR required normal peripheral blood counts with no evidence of extramedullary disease and <5% of blasts in a normocellular bone marrow, lasting more than one month; PR was defined as 5-25% of bone marrow blasts with normal peripheral blood counts or moderate pancytopenia and less than 5% of circulating blast cells. Treatment failures were registered as either induction deaths (ID) if patients died early or during marrow aplasia before CR could be ascertained, or resistant disease (RD) if criteria for PR were not fulfilled.

Cardiac toxicity was assessed by clinical and electrocardiographic examination for signs of failure or rhythm abnormalities. The others extrahematological toxicities were recorded according to the WHO grading system.¹⁰

The duration of disease-free survival (DFS) was measured from the day CR was documented to day

Table 1. Patient characteristics.

No. of patients	66
M/F	29/37
Age median (range)	66 (60-77)
WBC x 10 ⁹ /L median (range)	58 (1.8-295)
Plt x 10 ⁹ /L median (range)	69 (15-227)
Hgb g/L median (range)	87 (42-135)
LDH UI median (range)	1161 (240-12500)
Fever (>38°C) at diagnosis	30 (45%)
Documented infections	10 (15%)
Secondary leukemias	29 (44%)
AR	12
AREB	6
MF	2
t-AML	9
FAB	
M0	4
M1	15
M2	13
M4	22
M5	8
M6	2
M7	2
Trilineage dysplasia (<i>de novo</i> AML)	16/37 (43%)
immunophenotype (55 evaluated)	
CD34+	34 (62%)
CD7+	11 (20%)
CD14+	21 (37%)
cytogenetic (25 performed)	
no metaphases	7
low risk	1
intermediate risk	11
high risk	6

of relapse or last follow-up; patients who died without relapse were censored at the date of death. The duration of overall survival (OS) was measured from the time of initial therapy to date of death or last follow-up. The DFS and OS curves were drawn according to the Kaplan-Meier method. Differences among subgroups in the CR rate were compared using the Chi-square test.

Results

Among the 66 patients who received IDA plus ara-C and etoposide, 35 (53%) achieved CR, 23 (66%) after the first course. Nine were PR, for an overall response rate of 67%. Twenty-two were treatment failures: 13 (20%) RD and 9 (13%) ID (6 for sepsis, 2 for heart failure, 1 for pulmonary embolism). CR rate was 59% in *de novo* AML, 45 and 44% in cases with previous AHD and t-AML, respectively. Neither WBC count, LDH level, trilineage dysplasia nor fever at diagnosis were significant for the achievement of CR.

Phenotype was determined in 55 patients: 34 (62%) were positive for the the CD34 stem cell antigen; 11 were CD7 positive and they all coexpressed

CD34; 21 were CD14 positive and 10 coexpressed CD34. Only the CD7 positivity was significantly associated with chemoresistance since 7/11 (64%) had RD.

A successful karyotype was available in 18 of the 25 evaluated cases: among the 6 patients with unfavorable karyotype, one achieved CR lasting 19 months, 4 had RD, and one died early.

Of the 57 patients who survived the first cycle, 38 (67%) received the second planned course according to the protocol schedule, 19 did not. Five patients with absolute chemoresistance after the first course were assigned to salvage regimens but none of them achieved a response. Fourteen did not receive further aggressive chemotherapy, 6 for refusal and 8 for medical decision due to the toxicity or poor tolerance of the first course. Eight of these 14 patients were responders (4 CR, 4 PR) and went through to maintenance with LDara-C, the remaining 6 received only supportive or palliative chemotherapy.

Common side effects were nausea and vomiting, easily managed by i.v. antiemetics. All patients experienced profound granulocytopenia ($< 0.2 \text{ PMN} \times 10^9/\text{L}$) and thrombocytopenia (platelets $< 20 \times 10^9/\text{L}$). Mean days from the end of therapy to $\text{PMN} > 1.5 \times 10^9/\text{L}$ were 19.1 (range 11-30), to platelets $> 30 \times 10^9/\text{L}$ were 17.2 (range 10-30). Transfusion support was constantly required, with a mean of 7.1 packed RBCs and 17.2 platelets from random donor per cycle. The major toxicity consisted of infectious complications. At the study entry, 30 patients were febrile and 10 of them had a documented infection. During the induction phase, severe infections (WHO grade > 2) occurred in 16 patients. Six of them died early or while aplastic (1 for a *Candida tropicalis* sepsis, 1 *Pseudomonas*

aeruginosa sepsis and 4 for pneumonia). Overall, days with fever $> 38^\circ\text{C}$ were 3.4 per course. Two patients died for heart failure and 1 for pulmonary embolia: they all had a severe infectious complication at the time of death. Hepatic toxicity grade 3 was observed only in 1 patient. No other significant extrahematological toxicities were registered.

At the time of the analysis (May 30, 1997), 16 patients are alive and 50 have died. The projected median survival of the whole group is 14 months, with $< 10\%$ of patients alive after 3 years (Figure 1). One patient died in CR for myocardial infarction 1 month after the second course. Nine patients are in first CR, 26 relapsed. The median DFS was 13 months, with 20% of responding patients projected in continuous CR at 3 years (Figure 2).

Discussion

The unfavorable outcome of AML in the elderly is related both to the poor tolerance to chemotherapy and to the biological features of the disease. In a number of recent studies more than twenty per cent of patients failed to achieve a response due to resistance to chemotherapy.^{11,12} A conventional aggressive treatment should be the best choice but its value is still questioned due to the high incidence of ID. However, when lower dose chemotherapy is applied, a higher incidence of RD is observed without a reduction of ID.¹³ The purely supportive approach results not only in unfavorable survival but also in frequent hospitalization and poor quality of life.¹⁴ Sixty per cent or more of CR are reported with conventional induction chemotherapy but these results could be biased by patient's selection.¹⁵ Most of the hematologists agree that the majority of elderly patients would benefit from chemotherapy performed directly following diagno-




Figure 1. Overall survival.




Figure 2. Disease-free survival (n=35).

sis and prognostic score systems based on criteria readily available at the time of presentation have been proposed.^{16,17} Furthermore, models predicting overall survival rather than remission rate may be more appropriate in the elderly. We previously reported that LDara-C could be a useful option in patients who lack clinical features predictive for resistance to low-dose chemotherapy, i.e. an hypercellular marrow or a monocytic involvement.¹⁸ A low bone marrow cellularity has a favorable impact on the achievement of CR and duration of response when LDara-C therapy is applied.² Lower remission rates are reported in FAB subtypes M4/M5 suggesting that the clinical effect of LDara-C may be related to cell lineage.¹⁹ Thus, we designed to receive LDara-C those patients presenting with hypoplastic or oligoblastic leukemia without a monocytic involvement. Ten out of 22 (45%) achieved a CR without the hazards of aggressive chemotherapy, with a median DFS of 14 months. Conventional chemotherapy was restricted to AML cases with high leukemia burden, probably unresponsive to low-dose chemotherapy. Unlike in other studies,^{11,12} an AHD, t-AML or infections at diagnosis were not criteria of exclusion. However, 45 patients could not receive adequate chemotherapy due to a very poor performance status or a severe heart failure. Thus, only about 60% of elderly AML patients referred to our institution and judged to necessitate standard chemotherapy, could be treated.

The 53% CR rate achieved in the 66 patients treated with IDA, ara-C and etoposide is comparable with results of other studies (ref. #20-32; Table 2). We found no significant differences in CR rate between *de novo* AML, those preceded by an AHD and t-AML (59% vs 45% vs 44%). It has been shown that AML in the elderly present the characteristics

of the secondary AML even in most *de novo* cases.¹ In our series, 43% of the apparently *de novo* cases presented trilineage dysplasia. Furthermore, some patients recovered with dysplastic hematopoiesis, indicating that in older age group there may be patients presumed to have *de novo* AML who previously had an unrecognized myelodysplastic syndrome.

A significant association between elevated serum LDH and poor outcome was outlined by Ferrara²⁵ while others reported that prolonged remission was linked to elevated serum LDH and higher peripheral blood counts at diagnosis.²⁶ We could not demonstrate an impact on CR rate of serum LDH but patients with LDH < 800 UI have a better survival (465 vs 227 days, $p=0.09$).

While the CD34 expression failed to predict the outcome, CD7 was strongly associated with resistant disease: out of the 13 RD, 7 were registered among the 11 CD7 positive cases ($p < 0.05$). A successful cytogenetic study was available only in a minority of cases: as expected, the incidence of favorable karyotypes was negligible. Among the 6 patients with complex or unfavorable aberrations, only one achieved CR and 4 had RD.

In our study, 9 patients achieved a PR and, although it is conventionally regarded as a treatment failure, in this series of elderly patients the return to a nearly normal peripheral blood counts allowed a satisfying quality of life without supportive therapy until florid leukemic relapse occurred. Applying a global quality of life score, Bow *et al.*²⁶ reported that an improvement not different from that of the remitters could be observed in patients achieving PR.

Toxicity of induction treatment was mainly due to myelosuppression, bacterial and fungal infec-

Table 2. Results of induction chemotherapy in elderly AML patients.

Authors (year)	references	No pts	Age (median)	AHD	Complete remission %	Resistant leukemia %	OS (months)	DFS (months)
Baudard (1994)	15	238	n.r.	yes	33	45	3.5	9.7
Ruutu (1994)	20	25	72	yes	60	36	10	7
Jehn (1994)	21	32	68	yes	50	18	n.r.	7
Bigelow (1995)	13	31	66	no	42	42	8	n.r.
Dombret (1995)	12	173	68	no	59	41	n.r.	n.r.
Frenette (1995)	22	19	67	yes	37	17	n.r.	9.5
Stone (1995)	11	388	69	no	53	22	9	9
Ferrara (1996)	23	72	67	n.r.	57	30	9	12
Bow (1996)	24	67	68	n.r.	55	33	9.2	8.4
Pignon (1996)	25	233	59	no	66	184	12	17
Clavio (1996)	26	30	n.r.	yes	63	n.r.	n.r.	n.r.
Stasi (1996)	17	92	67	no	52	19	n.r.	9
Maslak (1996)	27	26	66	yes	58	34	8	10
Montillo (1996)	28	43	67	yes	49	39	8	11
Feldman (1997)	29	54	70	yes	50	50	8	6
present study		66	66	yes	53	47	14	13

AHD= antecedent haematologic disorder; OS= overall survival; DFS= disease free survival

tions representing the major source of morbidity and mortality. Colony stimulating factors were not routinely delivered, since randomized studies with GM-CSF^{11,23} or G-CSF¹² failed to demonstrate any impact on ID rate. Severe heart failure was recorded in 2 patients and both have died with a concomitant infectious complication. The overall survival and remission duration are in keeping with those reported by others (Table 2) but less than 10% of patients are projected to be alive and disease free at 3 years. Long-term survival remains an unresolved problem in elderly patients with AML and the choice of post-induction therapy may be crucial. Results of high-dose ARA-C have been disappointing²² and it has been shown that a unique consolidation course may be as effective as more prolonged treatments.³³ The duration of hospitalization for our patients completing the induction protocol was nearly two months. An intensive consolidation regimen would request further hospitalization and could result in unacceptable toxicity in front of any improvement of DFS. Thus we decided to deliver a maximum of two courses of intensive chemotherapy, irrespective whether CR was achieved after the first or the second course. The *maintenance* treatment with LDara-C was chosen for the suggested efficacy in prolong DFS³⁴ with negligible extramedullary toxicity. Since also in the present study the majority of relapsed or refractory patients either failed subsequent salvage therapy or did not receive any, it can be concluded that the major impact on survival comes from the initial treatment, not from salvage therapy.

In conclusion, the balance between the benefits and risks of intensive chemotherapy is particularly delicate in older patients. The best therapeutic choice is not the most aggressive but the best balanced. Our regimen with IDA at the dose of 8

mg/sqm for 3 days instead of conventional 10-12 mg/sqm is feasible and effective. The dosage attenuation does not result in a reduced exposure to the drug, since the idarubicin elimination is impaired in patients over sixty.⁶ Furthermore, there is some clinical evidence suggesting that 12 mg/sqm for 3 days is probably too toxic for most elderly patients.³⁶ It's unlikely that far more better results can be achieved by conventional chemotherapy. Alternative approaches are advisable to overcome the intrinsic chemoresistance of AML of the elderly. MDR revertants are currently studied in clinical trials and a greater understanding of drug pharmacodynamics has lead to the use of novel chemotherapeutic regimens. The efficacy and tolerability of fludarabine, ara-C and G-CSF (FLAG) in MDS/AML has been confirmed in clinical studies.²⁸ Addition of IDA to FLAG regimen³⁵ may further improve clinical results.

References

1. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). *Leukemia* 1996; 10(suppl.1):S33-S35.
2. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of nonlymphocytic leukemia in the elderly. *J Clin Oncol* 1990; 8:272-9.
3. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. *Blood* 1992; 79:3267-73.
4. Testi R, Mattii L, Di Simone D, et al. Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines. *Leuk Res* 1995; 19:257-61.
5. Wiernick PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. *Blood* 1992; 79:313-9.
6. Leoni F, Ciolli S, Giuliani G, et al. Attenuated-dose idarubicin in acute myeloid leukemia of the elderly: pharmacokinetic study and clinical results. *Br J Haematol* 1995; 90:169-74.
7. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. *Ann Intern Med* 1985; 103:626-9.

8. Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage dysplasia. *Br J Haematol* 1987; 66:445-50.
9. Mitelman F. An International System for Human Cytogenetic Nomenclature. Basel: Karger, 1995.
10. World Health Organization. Handbook for reporting results in cancer treatment. W.H.O. offset publication 1979; no.48, Geneva.
11. Stone RM, Berg DT, George SL et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. *Cancer and Leukemia Group B. N Engl J Med* 1995; 332:1671-7.
12. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. *AML Cooperative Study Group. N Engl J Med* 1995; 332:1678-83.
13. Bigelow CL, Kopecky K, Files JC, et al. Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group Study. *Am J Hematol* 1995; 48:228-32.
14. Lowenberg B. Treatment of the elderly patient with acute myeloid leukaemia. *Baillière's Clin Haematol* 1996; 9:147-59.
15. Baudard M, Marie JP, Cadiou M, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. *Br J Haematol* 1994; 86:82-91.
16. Johnson PR, Ryder WDJ, Liu Yin JA. Validation of a model to predict survival in elderly patients with acute myeloid leukaemia. *Br J Haematol* 1995; 90:954-6.
17. Stasi R, Venditti A, Del Poeta G, et al. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors. *Cancer* 1996; 77:2476-88.
18. Pascarella A, Marrani C, Leoni F et al. Low-dose cytosine arabinoside in patients with acute myeloid leukemia not eligible for standard chemotherapy. *Leuk Lymphoma* 1995; 18:465-9.
19. Lutz D, Kieger O, Ihle R, et al. Different response rate to low-dose cytosine arabinoside in acute myeloid leukemia subtypes. *Semin Oncol* 1987; 14:121-5.
20. Ruutu T, Almqvist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. *Finnish Leukemia Group. Leukemia* 1994; 8:11-5.
21. Jehn U. Phase II-trial of double-consolidation following intensive induction treatment for improvement of survival in elderly patients with acute myeloid leukemia. *Leuk Lymphoma* 1994; 12:435-40.
22. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. *N Engl J Med* 1994; 331:896-903.
23. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E 1490). *Blood* 1995; 86:457-62.
24. Frenette PS, Desforges JF, Schenkein DP, et al. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. *Am J Hematol* 1995; 49:48-55.
25. Ferrara F, Mirto S. Serum LDH as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. *Br J Haematol* 1996; 92:627-31.
26. Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. *J Clin Oncol* 1996; 14:1345-52.
27. Pignon B, Witz F, Desablens B, et al. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease free survival can be obtained using a unique consolidation course. *Br J Haematol* 1996; 94:333-41.
28. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. *Haematologica* 1996; 81:513-20.
29. Maslak PG, Weiss MA, Berman E, et al. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. *Leukemia* 1996; 10:32-9.
30. Montillo M, Gimema Group. Preliminary results of a GIMEMA pilot study in the treatment of acute myeloid leukemia in the elderly (Abstract). *Blood* 1996; 88(suppl 1):862a.
31. Feldman EJ, Seiter K, Damon I, et al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. *Leukemia* 1997; 11:485-9.
32. Jackson GH, Taylor PRA, Iqbal A, et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. *Leukemia* 1997; 11:1193-96.
33. Harausseu JL, Milpied N, Briere J, et al. Double intensive consolidation chemotherapy in adult acute myeloid leukemia. *J Clin Oncol* 1991; 9:1432-7.
34. Lowenberg B, Fiere D, Zittoun R, et al. Mitoxantrone versus daunorubicin in induction of acute myelogenous leukemia in elderly patients and low dose Ara-C versus control as maintenance. An a EORTC phase III trial (AML-9) [abstract]. *Haematologica* 1991; 76(Suppl 4):353a.
35. Parker JE, Cullis GO, Crotty G, et al. FLAG-idarubicin chemotherapy for the treatment of high risk MDS or AML [abstract]. *Br J Haematol* 1997; 97(Suppl 1):16a.
36. Bassan R, Barbui T. Remission induction therapy for adults with acute myeloid leukemia: towards the ICE age? *Haematologica* 1995; 80:82-90.



A SINGLE HIGH DOSE OF IDARUBICIN COMBINED WITH HIGH-DOSE ARA-C (MSKCC ALL-3 PROTOCOL) IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. EXPERIENCE AT THE UNIVERSITY "LA SAPIENZA" OF ROME

ANNA MARIA TESTI, MARIA LUISA MOLETTI, FIORINA GIONA, LUCIANA ANNINO, SABINA CHIARETTI, ILARIA DEL GIUDICE, ELISABETTA TODISCO, GIANNAMARIA D'ELIA, ANTONELLA FERRARI, WILLIAM ARCESE, FRANCO MANDELLI

Sezione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia. Università La Sapienza, Rome, Italy

ABSTRACT

Background and Objective. The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL). In an attempt to minimize the non-hematologic toxicity and obtain a potent antileukemic effect, MSKCC activated a pilot study in previously treated adult ALL, using HD-ARA-C combined with idarubicin administered as a single high-dose infusion. We herein report our experience with a series of pediatric and adult high risk ALL and NHL patients treated with the protocol above, which confirms its feasibility, response rate and individual compliance.

Methods. In a clinical phase II study the combination of a single high dose (HD) idarubicin and HD cytosine-arabioside (ARA-C), as designed at the Memorial Sloan Kettering Cancer Center, was applied to 70 adults and children with refractory or early relapse acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic non-Hodgkin's lymphoma (NHL). Therapy consisted of HD-ARA-C 3 g/m²/d

on days 1-5, idarubicin 40 mg/m² on day 3, prophylactic intrathecal methotrexate on days 1 and 4, and G-CSF 5 mg/kg/d s.c. from day 7 to hematopoietic reconstitution (PMN >0.5×10⁹/L).

Results. Fifty-five of the 70 patients (78%) achieved complete remission (CR), four died in aplasia due to infection and 11 were non-responders. Recovery of blood counts occurred at a median of 21 days from the start of treatment. Non-hematologic side effects were extremely limited and consisted predominantly of infections.

Interpretation and Conclusions. In view of the highly unfavorable series of patients selected, this study confirms the feasibility and antileukemic activity of the HD-idarubicin + HD-ARA-C combination in patients with refractory and early relapse ALL and NHL. The excellent tolerance to this regimen does not preclude bone marrow transplantation as post-remission treatment.

Key words: acute lymphoblastic leukemia, chemotherapy, cytosine arabioside, idarubicin, relapse

The anthracycline analog idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL). Three previous Italian multicenter studies (ALL R85; ALL R87; ALL R93) used standard dose idarubicin, administered daily or every other day, in association with intermediate or high dose (HD) cytosine-arabioside (ARA-C) as reinduction therapy for relapsed or refractory adult and pediatric ALL patients.^{1,2} In our experience, these combinations showed antileukemic activity but caused severe gastrointestinal toxicity frequently associated to serious and persistent infections. At the Memorial Sloan Kettering Cancer Center (MSKCC), New York, idarubicin has been used as once a week treatment or in continuous infusion in

adult relapse ALL.³ Both protocols showed significant mucosal toxicity (limiting dose intensity) suggesting that protracted low level exposure to idarubicinol, the active metabolite of idarubicin, in fact has a very long half-life (> 48 hours).

In an attempt to minimize the non-hematologic toxicity and obtain a potent antileukemic effect, MSKCC activated a pilot study in previously treated adult ALL, using HD-ARA-C combined with idarubicin administered as a single high dose infusion. A phase I study with an escalating dose of idarubicin was first carried out to determine the phase II dose. An idarubicin dose of 40 mg/m² was well tolerated and effective in relapsed and refractory adult ALL patients.⁴

We herein report our experience with a series of

Correspondence: Dr. Anna Maria Testi, sezione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, via Benevento 6, 00161 Rome, Italy. Tel. international +39.6.857951 (switchboard); +39.6.85795239 (office). Fax: international +39.6.44241984.

Acknowledgements: This work was supported by CNR (Consiglio Nazionale delle Ricerche), Progetto Finalizzato "ACRO", contract N° 95.00450.PF39, Rome. Idarubicin was generously supplied by Pharmacia, Milan.

pediatric and adult high risk ALL and NHL patients treated with the protocol above, which confirms its feasibility, response rate and individual compliance.

Patients and Methods

The current series includes patients with refractory or early relapse ALL. Patients with lymphoid blastic crisis (BC) of chronic myelogenous leukemia (CML) and hematological relapse of T-lymphoblastic non-Hodgkin's lymphoma (NHL) were also included. Patients were eligible for this regimen when the following pre-requisites were fulfilled: 1) age under 60 years; 2) non-mature B-ALL; 3) primary resistance ALL to intensive first line treatment (AIEOP-BFM as a therapy for children, GIMEMA-5-drug induction for adults); 4) early first ALL or T-lymphoblastic NHL hematological relapse (adults: first remission < 24 months; children: first remission < 30 months); 5) second or subsequent hematologic relapse; 6) lymphoid BC of CML.

Prior to therapy, patients gave their consent after having been advised about the investigational nature of the study, as well as of the potential risks.

The protocol (Figure 1) consisted of ARA-C 3 g/m²/d intravenously (i.v.) over a 3 hour infusion for five days, idarubicin 40 mg/m² i.v. at day 3 and prophylactic intrathecal methotrexate (MTX dose per age) at day 1 and 4. G-CSF (Lenograstim) was subcutaneously (s.c.) administered at the dose of 5 mg/kg/d starting on day 7 (48 hrs after the last dose of ARA-C) and continuing until the granulocyte count exceeded 0.5×10⁹/L for two consecutive days. Prednisone was also given at a dose of 0.5 mg/kg/d during treatment. For the prophylaxis of HD-ARA-C-induced photophobia and conjunctivi-

tis, all patients received glucocorticoid eyedrops every 8 hours starting before the first dose and continuing for 48 hrs after the last dose of HD-ARA-C.

Post-remission therapy was not planned, but nonetheless, allogeneic bone marrow transplant (BMT) from an HLA identical sibling or an unrelated volunteer donor or with umbilical cord blood stem cells was mandatory in responsive patients. Toxicity was defined according to the World Health Organization (WHO) grading system.⁵ Evaluation of the antileukemic efficacy was based on CALGB criteria.^{6,7}

Results

From January 1995 to April 1997, 70 patients (47 males and 23 females) were enrolled in this study. Their pre-therapeutic characteristics are summarized in Table 1. Forty-four patients were children (age < 15 years) and 26 were adults (age > 15 years). The immunophenotype was of B-cell lineage in 43, of T-cell lineage in 19 and hybrid (My+) in 8. Fifty-one patients were in first and eight were in second bone marrow relapse; 10 were refractory to intensive first line therapy and 1 patient presented a lymphoid BC of CML. The median duration of initial remission for patients treated in first relapse was 11 months (3-30 months). All 44 children had received standard first line treatment according to the AIEOP 88-91-95 BFM-like protocols,⁸ consisting of an 8-week induction with prednisone, vincristine (VCR), daunorubicin and L-asparaginase for the first 4 weeks followed by cyclophosphamide, ARA-C and 6-mercaptopurine (6-MP) for the subsequent 4 weeks. Induction was followed by 9 courses of multidrug




Figure 1. MSKCC ALL-3 protocol: induction schema.

chemotherapy (including HD-MTX, ARA-C and L-asparaginase) for high risk patients (9 children) and by HD-MTX consolidation, VCR, adriamycin, dexamethasone reinduction and standard MTX, 6-MP maintenance for standard risk patients (6 children). One child treated for his second relapse was reinduced with 2 blocks of the BFM-REZ 85 protocol⁹ and a weekly standard dose of idarubicin and VCR. Front-line therapy for the 26 adult patients was as follows: the GIMEMA 0288 protocol^{10,11} in 3; the GIMEMA 0394 pilot protocol¹² (8-week induction: standard dose ARA-C, etoposide, idarubicin combination followed by dexamethasone, VCR, L-asparaginase) in 12; Verona ALL protocol (high-dose anthracyclin) in 3; Stanford or LSA2-L2 protocols in 6 cases initially diagnosed as T-lymphoblastic NHL and hydroxyurea plus interferon- α in the patient with BC-CML.

Fifty-five of the 70 patients (78%) achieved complete remission (CR). In 11 non-responders (16%), leukemia recovered after marrow aplasia; four patients died during the aplastic phase from sepsis. Thirty-seven of the 44 children achieved CR (84%), while 18 of the 26 adults (69%) were complete responders (Table 2).

Treatment induced profound myelosuppression in all patients; G-CSF was administered to all patients, as planned. The median time to granulocytes $>0.5 \times 10^9/L$ and to thrombocytes $>50 \times 10^9/L$ was 17 days (8-36 days) and 22 days (5-41 days) from the start of treatment, respectively.

A summary of the extra-hematological side effects is reported in Table 3. Infection was the most frequent complication; twenty grade III-IV infective episodes were observed. Forty-eight febrile episodes occurred during neutropenia: bacterial infections were documented in 36 cases (12 sepsis; 4 fatal) and fungal in 8 (1 sepsis). Twelve patients experienced gastrointestinal toxicity including oral mucositis and diarrhea (WHO \geq II). No severe cardiac events were observed after one induction cycle; one heavily pre-treated child experienced a dilatative cardiomyopathy which precluded a post-remission bone marrow transplant following a second identical induction course, administered as a post-remission phase. No therapy-related pulmonary toxicity was observed. A transient cerebellar toxicity was observed in one child a few days after high-dose ARA-C infusion.

Forty-nine of the 55 responders are evaluable for the follow-up. Three patients died in CR from infections; 2 were withdrawn for consolidation therapy-related toxicity; 12 relapsed at a median time of 4 months and 32 were considered eligible for bone marrow transplant. Twenty-one underwent an allogeneic BMT (10 from an HLA identical sibling, 4 from an unrelated donor and 7 with umbilical cord blood cells) and 3 received autologous BMT. Sixteen transplanted patients are cur-

Table 1. Patients characteristics.

	Total	Age < 15 yrs	Age > 15 yrs
Number of patients	70	44	26
Sex: M/F	47/23	29/15	18/8
Age			
median (years)	10	4,11	20
range	0.10-44	0.10-15	15.5-44
Phenotype			
B-lineage (Ph+)	43 (5)	31 (2)	12 (3)
T-lineage	19	9	10
Hybrid	8	4	4
Disease status			
primary refractory	10	4	6
2nd relapse	8	6	2
1st relapse	52	34	18
Previous treatments			
BFM-like protocols	42	42	-
GIMEMA 0394	12	-	12
GIMEMA 0288	3	-	3
GIMEMA "Verona"	5	2	3
"Stanford" - LSA ₂ -L ₂	6	-	6
Others	2	-	2

Table 2. Induction results.

	Total	Age < 15 yrs	Age > 15 yrs
Number of patients	70	44	26
Complete Remissions	55 (78%)	37 (84%)	18 (69%)
Induction deaths	4 (6%)	3	1
Resistants	11 (16%)	4	7

Table 3. Extrahematologic toxicity.

	WHO=3	WHO=4
Oral mucositis	5	2
Diarrhea	6	3
Hepatic	3	2
Cardiac	1	0
Neurologic	1	-
Renal	3	-

rently living in CR with a median time from transplant of 7 months (range 3-12 months); one died from transplant-related toxicity and 7 relapsed at a median of 6 months from transplant.

The other 8 responding patients received different chemotherapeutic maintenance treatments: four patients are in CR and in a waiting list for an unrelated BMT; four relapsed at a median time of 6 months while the search for an unrelated volunteer bone marrow donor was still ongoing.

Discussion

The efficacy of idarubicin associated to HD-ARA-C has been demonstrated in high risk ALL patients^{1,2,3,13} and previously reported in this journal.^{14,15} In the previous Italian multicenter experience, the two drugs were utilized in combination, at different doses, and in timing of administration, as reinduction therapy in refractory or relapse ALL (ALL-R-85, -87, -93 protocols). ARA-C was given at high/intermediate dose (3 g/m²/12 hrs or 1 g/m²/d x 6 doses) and idarubicin was administered following ARA-C infusion at a standard dose (12 or 10 or 5 mg/m²/d), either daily or every other day. The ALL-R-85 and -87 studies included both children and adults with pretreated ALL, while in the ALL-R-93 protocol only children were enrolled. A total of 88, 147 and 80 patients, respectively, were treated with these three regimens. The combination of ARA-C and idarubicin showed antileukemic efficacy in all three protocols with CR rates of 59, 66 and 84%, respectively. Children had a better induction response as compared to adults, with CR rates ranging between 68 and 84% compared to 54-55% for adults. However, in all three studies gastrointestinal toxicity with mucositis and diarrhea, associated to serious bacterial and fungal infections, was the main side effect. Most of the complete responders suffered from severe or persistent infections precluding further intensive post-remission treatment. Only 40-50% of responders resulted eligible for BMT. Similar observations on idarubicin + HD-ARA-C efficacy and toxicity have been witnessed at MSKCC in adult pretreated ALL patients.³ With the aim of minimizing the extra-hematological toxicity, the current MSKCC (ALL-3) protocol uses HD-ARA-C combined with idarubicin administered as a single high dose (40 mg/m²) in pretreated adult ALL.⁴

In agreement with MSKCC investigators, we applied the ALL-3 induction regimen to our high-risk ALL patients including adults and children. Seventy patients were treated and 55 (78%) achieved CR. The protocol was restricted exclusively to patients who were refractory to intensive first-line therapy, or to patients who were heavily pretreated and relapsed after a very brief initial remission (median CR length 11 months). Taking these prerequisites into account, which led to the selection of a highly unfavorable group of ALL, the CR rate of 78% clearly indicates the high efficacy of HD-idarubicin and HD-ARA-C regimen. These data can be compared with our previous trials, using the HD-ARA-C and idarubicin combination; again, children had a significantly better induction response com-

pared to adults: 84% and 69%, respectively. Despite the intensive previous therapy, including drugs administered at high doses, the extra-hematological side effects were acceptable. Infection was the most frequent complication occurring in 44 cases; gastrointestinal toxicity was less frequent but severe, compared to that observed in the previous Italian multicenter studies. The majority of evaluable responder patients (32/49) were considered eligible for aggressive post-remission management, including allogeneic BMT.

The feasibility and the efficacy of this regimen suggest its application in cooperative studies, for the treatment of adults and children with refractory and relapse ALL. A multicenter study is necessary to delineate the incidence and the duration of response.

References

- Giona F, Testi AM, Amadori S, et al. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. *Ann Oncol* 1990; 1:51-5.
- Giona F, Testi AM, Annino L, et al. Treatment of primary refractory and relapsed acute lymphoblastic leukemia in children and adults: the GIMEMA, AIEOP experience. *Br J Haematol* 1994; 86:55-61.
- Berman E, Raymond V, Gee T, et al. Idarubicin in acute leukemia: results of studies at Memorial Sloan Kettering Cancer Center. *Semin Oncol* 1989; 16 (Suppl. 2):30-4.
- Weiss M, Maslak P, Megherian L, Scheinberg D. A phase I trial of a single high dose of idarubicin combined with high dose cytarabine (ARA-C) as induction therapy in relapsed and refractory adult patients with acute lymphoblastic leukemia (ALL). *Blood* 1995; 86 (suppl. 1):786a.
- World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO Publication 1979:38.
- Ohnuma T, Rosner F, Levy RN, et al. Treatment of adult leukemia with L-asparaginase. *Cancer Chemother Rep* 1971; 55:269-75.
- Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. *Blood* 1982; 60:454-9.
- Conter V, Rizzari C, Arico M, et al. Preliminary results of the AIEOP 1991 study for childhood acute lymphoblastic leukemia (ALL). *Med Pediatr Oncol* 1995; 25:283.
- Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM85). A relapse study of the BFM group. *Blood* 1991; 78:1166-72.
- Annino L, for the GIMEMA cooperative group. GIMEMA multicentric trial for treatment of acute lymphoblastic leukemia in adults (ALL 0288). Interim report. *Blood* 1992; 80(suppl. 1):28.
- Amadori S, Annino L, Ferrari A, et al. Therapy of adult acute lymphoblastic leukemia. Preliminary results of the GIMEMA ALL 0288 study. In: R Buckner *et al.*, eds. *Acute leukemia IV*. Berlin: Springer Verlag; 1994. p. 432-6.
- Annino L, Ferrari A, Del Poeta G, et al. Myeloid-like induction for adult acute lymphoblastic leukemia (ALL). The GIMEMA ALL 0394 Pilot study. *Proc XIII Meeting International Society of Hematology, Istanbul, Turkiye, September 7-8, 1995*.
- Arcese W, Amadori S, Meloni G, et al. Allogeneic and autologous bone marrow transplantation for intensification of salvage therapy in patients with high risk advanced acute lymphoblastic leukemia. *Semin Hematol* 1991; 28:116-21.
- Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. *Haematologica* 1995; 80:280-91.
- Lerede T, Bassan R, Rossi A, et al. Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. *Haematologica* 1996; 81:442-9.



IDARUBICIN IN LOW-GRADE NON-HODGKIN'S LYMPHOMAS

PIER LUIGI ZINZANI

Institute of Hematology and Medical Oncology "Seràgnoli", University of Bologna, Bologna

ABSTRACT

The majority of responses produced in patients with low-grade lymphomas are unique among non-Hodgkin's lymphomas (NHL), and even with a more intensive chemotherapy regimen, they are only partial; the very few complete responses which are induced are usually of short duration and do not influence overall survival. There is, therefore, a need for new approaches to the management of low-grade NHLs. Studies are currently in progress to assess the potential benefits in the treatment of NHL offered by new drugs, including fludarabine, idarubicin and 2-chlorodeoxyadenosine. In order to evaluate Idarubicin in combination with purine analogs, we used a combination of fludarabine and idarubicin, called the FLU-ID

regimen, to treat 10 patients with recurrent low-grade NHL. Of the 10 patients, 2 (20%) achieved complete response, 5 (50%) partial response, and the remaining 3 showed no benefit from the treatment. The 2 CR patients are still in remission after 12 and 14 months, respectively. The median duration of overall survival of all patients was 18 months. These results indicate the efficacy of the FLU-ID regimen in inducing a good remission rate with moderate side effects in recurrent low-grade NHL. On the basis of this pilot study, we planned a cooperative randomized trial for untreated patients.

Key words: non-Hodgkin lymphomas, idarubicin

Low-grade lymphomas are unique among non-Hodgkin's lymphomas (NHL) because in the early stages of disease most patients do not require treatment, and when treatment becomes necessary, they can be maintained on non-aggressive therapy, such as single alkylating agents, for many years. However, the majority of responses produced in these patients, even with more intensive chemotherapy regimens, are only partial, and the very few complete responses which are induced are usually of short duration and do not influence overall survival. There is, therefore, a need for new approaches to the management of low-grade NHLs. Idarubicin has been proven to be effective in different hematological neoplasms.¹⁻⁴ Studies are currently in progress to assess the potential benefits in the treatment of NHL offered by new drugs, including fludarabine, idarubicin and 2-chlorodeoxyadenosine.

Idarubicin, a derivative of daunorubicin, has been shown to be well-tolerated and effective in the treatment of low-grade NHL, producing response rates of up to 65% in various clinical studies.⁵⁻⁸ Since this anthracycline can be administered orally as well as intravenously, it is an excellent candidate for the treatment of selected groups of patients such as the elderly and those with indolent diseases not requiring aggressive intervention therapy.

Case *et al.*⁶ conducted a phase II study to assess the efficacy and toxicity of oral idarubicin in 46 patients with previously treated low-grade NHL.

Each course of treatment consisted of a total of 45 mg/sqm of idarubicin, administered orally on three consecutive days, with intervals of three weeks between treatment courses. Complete remissions were observed in 10 patients (22%) and partial responses were seen in 16 (36%) patients, resulting in an overall tumor response rate of 58%. Idarubicin was generally well-tolerated, and no patients withdrew from the study due to treatment toxicity. Mild hematological toxicity was observed and was dose-limiting at higher doses of idarubicin. The major non-hematological symptom was nausea/vomiting which was experienced by 50% of the patients. Clinically relevant cardiac toxicity was not observed. Significant but mild changes in the resting cardiac ejection fraction were detected in four patients.

Low-grade NHLs are commonly treated by single alkylating agents such as chlorambucil. The advent of the new oral cytotoxic anthracycline, Idarubicin, has prompted an assessment of its efficacy within current treatment regimens in the management of patients with low-grade NHL. The identification of discrete prognostic groups of patients with low grade NHL has allowed an assessment of the efficacy of the treatment with respect to the prognostic risk status of patients. Proctor *et al.*⁸ defined a treatment protocol (CID) for untreated patients with low-grade NHL as described below:

- chlorambucil 20 mg/sqm/day, days 1-3
- idarubicin 10 mg/sqm/day, days 1-3
- dexamethasone 4 mg bd., days 1-5

given for 6 courses.

The rationale behind the treatment regimen was to expose the tumor, over a prolonged period of time, to the alkylating activity of chlorambucil, the cytotoxic and apoptotic activity of Idarubicin, and the apoptotic effect of dexamethasone. Under this regimen the lymphoma received sustained exposure to anti-tumour therapy for 3-5 days, with an additional therapeutic effect provided by the active metabolite of idarubicin, idarubicinol, which remains in the bloodstream for up to seven days.⁹

The median age of the population treated was 54 years: 24 females and 38 male patients. 79% were stage IV, 76% had follicular histology and the remaining patients had other low-grade histological groups. The overall response rate was 77%; the combined groups of patients achieving CR was 50% with patients achieving GPR and PR of 27%. The remaining 23% of the patients showed responses lower than PR. In this phase II study, the overall response rate for those with follicular histology was 88%.

Concerning toxicity, the majority of patients (35-50%) showed either mild (grade I and grade II, according to the WHO grading system) or no treatment-related toxicity throughout the six cycles of therapy. Only a small number of patients (1%) showed grade IV toxicity during the fifth course of treatment, although none of these patients required hospitalization for management of their symptoms. Overall, the CID treatment was well-tolerated, particularly in elderly patients, with dyspepsia being reported as the major adverse event; no patient suffered from alopecia.

As a consequence of the encouraging results from the phase II study, a phase III study has been undertaken to evaluate the efficacy of CID at the doses indicated above, in comparison with equivalent doses of chlorambucil and dexamethasone (CD) therapy in patients with low-grade NHL. These patients will undergo six courses of induction therapy with CID or CD at intervals of three weeks. Following determination of the tumor response rates and administration of radiotherapy to treat initial areas of bulky disease, patients will be randomized to receive one of two consolidation/maintenance therapies: no further therapy or α -interferon will be administered.

In order to evaluate Idarubicin in combination with purine analogs, we used a combination of Fludarabine and Idarubicin, called the FLU-ID regimen, to treat 10 patients with recurrent low-grade NHL.¹⁰ The FLU-ID regimen was as follows: fludarabine 25 mg/sqm i.v. on days 1 to 3 and idarubicin 12 mg/sqm i.v. on day 1. Of the 10 patients, 2 (20%) achieved complete response, 5 (50%) partial response, and the remaining 3 showed no benefit from the treatment. The 2 CR patients are still in remission after 12 and 14 months, respectively. The

median duration of overall survival of all patients was 18 months. The major toxic effects observed were neutropenia (40%) and infections and/or febrile episodes (15%); no fatalities occurred due to the side effects of the drug. These results indicate the efficacy of the FLU-ID regimen in inducing a good remission rate with moderate side effects in recurrent low-grade NHL.

On the basis of this pilot study, we planned a cooperative randomized trial for untreated patients with these considerations:

- 1) use, at diagnosis, of the *International Prognostic Index* to stratify patients before treatment to deliver a risk-based therapy;
- 2) introduction of fludarabine in first-line treatment because of its activity in slow proliferating and resting cells through the apoptotic way, and its promising activity in previously treated low-grade NHL;
- 3) introduction of a fludarabine-idarubicin (FLU-ID) combination-containing regimen, because, among the typical drugs, idarubicin has shown interesting therapeutic results while reducing cardiotoxicity and alopecia;
- 4) use of a MACOP-B-like regimen, the CIVOP-B (cyclophosphamide, idarubicin, vincristine, prednisone, VP-16, and bleomycin) protocol, as conventional therapy for high-risk patients;
- 5) the role of α -interferon as maintenance therapy in prolonging disease-free survival. This study has been ongoing since September 1995 and, so far, 205 patients have been enrolled.

References

1. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? *Haematologica* 1995; 80:82-90.
2. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. *Haematologica* 1995; 80:280-91.
3. Lerede T, Bassan R, Rossi A, et al. Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. *Haematologica* 1996; 81:442-9.
4. Bertini M, Freilone R, Botto B, et al. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B. *Haematologica* 1997; 82:309-13.
5. Lopez M, Di Lauro L, Papaldo P. Oral idarubicin in non-Hodgkin's lymphomas. *Invest New Drug* 1986; 4:263-7.
6. Case DC Jr, Hayes DM, Gerber M, et al. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. *Cancer Res* 1990; 50:6833-5.
7. Case DC Jr, Gerber M, Gams RA, et al. Phase II study of intravenous idarubicin in unfavourable non-Hodgkin's lymphoma. *Leuk Lymphoma* 1993; 10:73-9.
8. Proctor SJ, Taylor PRA. The use of oral idarubicin, chlorambucil and dexamethasone in low-grade non-Hodgkin's lymphoma [abstract]. Sixth International Conference on Lymphoma, Lugano, Switzerland. June 5-8, 1996.
9. Elbaek K, Ebbelohj E, Jakobsen A, et al. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumour activity and side effects. *Clin Pharmacol Ther* 1989; 45:627-34.
10. Zinzani PL, Bendandi M, Gherlinzoni F, et al. FLU-ID (Fludarabine and Idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma. *Haematologica* 1996; 81:168-71.

